BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1063] [Article Influence: 563.0] [Reference Citation Analysis]
Number Citing Articles
1 Chu HH, Kim JH, Yoon HK, Ko HK, Gwon DI, Kim PN, Sung KB, Ko GY, Kim SY, Park SH. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. J Vasc Interv Radiol. 2019;30:1533-1543. [PMID: 31471190 DOI: 10.1016/j.jvir.2019.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
2 Qiu L, Zhan K, Malale K, Wu X, Mei Z. Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chai ZT, Zhang XP, Shao M, Ao JY, Chen ZH, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Wu MC, Lau WY, Cheng SQ. Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Ann Transl Med 2021;9:247. [PMID: 33708874 DOI: 10.21037/atm-20-2229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 2020;30:2302-11. [DOI: 10.1007/s00330-019-06546-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Nakamura Y, Higaki T, Honda Y, Tatsugami F, Tani C, Fukumoto W, Narita K, Kondo S, Akagi M, Awai K. Advanced CT techniques for assessing hepatocellular carcinoma. Radiol Med 2021;126:925-35. [PMID: 33954894 DOI: 10.1007/s11547-021-01366-4] [Reference Citation Analysis]
6 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
7 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
8 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
9 Wei J, Jiang H, Gu D, Niu M, Fu F, Han Y, Song B, Tian J. Radiomics in liver diseases: Current progress and future opportunities. Liver Int 2020;40:2050-63. [PMID: 32515148 DOI: 10.1111/liv.14555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1177. [PMID: 32392752 DOI: 10.3390/cancers12051177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Westin J, Aleman S, Castedal M, Duberg A, Eilard A, Fischler B, Kampmann C, Lindahl K, Lindh M, Norkrans G, Stenmark S, Weiland O, Wejstål R. Management of hepatitis B virus infection, updated Swedish guidelines. Infectious Diseases 2020;52:1-22. [DOI: 10.1080/23744235.2019.1675903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Rubin JN, Gilman CAL, Gasmi B, Stern WR, Hernandez JM, Koh C. Hepatocellular Carcinoma Where You Least Expect It. Am J Gastroenterol 2020;115:1134-6. [PMID: 32618667 DOI: 10.14309/ajg.0000000000000616] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mendiratta-lala M, William M, Shampain K, Zhang A, Jo A, Moorman S, Aslam A, Mature K, Davenport M. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiology: Imaging Cancer. 2020;2. [PMID: 33778692 DOI: 10.1148/rycan.2020190024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
15 Onyirioha K, Mittal S, G Singal A. Is hepatocellular carcinoma surveillance in high-risk populations effective? Hepat Oncol 2020;7:HEP25. [PMID: 32774835 DOI: 10.2217/hep-2020-0012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther 2019;49:308-20. [PMID: 30569507 DOI: 10.1111/apt.15082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Dahdaleh FS, Naffouje SA, Sherman SK, Kamarajah SK, Salti GI. Tissue Diagnosis Is Associated With Worse Survival in Hepatocellular Carcinoma: A National Cancer Database Analysis. Am Surg 2021;:3134821991983. [PMID: 33830824 DOI: 10.1177/0003134821991983] [Reference Citation Analysis]
18 Fan W, Yuan G, Fan H, Li F, Wu Y, Zhao Y, Yao W, Wang Y, Xue M, Yang J, Li J. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clin Ther 2019;41:1463-76. [PMID: 31303279 DOI: 10.1016/j.clinthera.2019.04.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
19 Ling YH, Chen JW, Wen SH, Huang CY, Li P, Lu LH, Mei J, Li SH, Wei W, Cai MY, Guo RP. Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. BMC Cancer 2020;20:607. [PMID: 32600297 DOI: 10.1186/s12885-020-07097-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 48.0] [Reference Citation Analysis]
21 O'Rourke C, Jayaraman S, El-Maraghi RH, Singal AG, Kielar AZ. Chronic Liver Disease and Liver Cancer: What the Hepatologists, Oncologists, and Surgeons Want to Know from Radiologists. Magn Reson Imaging Clin N Am 2021;29:269-78. [PMID: 34243916 DOI: 10.1016/j.mric.2021.05.001] [Reference Citation Analysis]
22 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
23 Tang A, Abukasm K, Moura Cunha G, Song B, Wang J, Wagner M, Dietrich CF, Brancatelli G, Ueda K, Choi J, Aguirre D, Sirlin CB. Imaging of hepatocellular carcinoma: a pilot international survey. Abdom Radiol 2021;46:205-15. [DOI: 10.1007/s00261-020-02598-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mohammed ES, El-Beih NM, El-Hussieny EA, El-Ahwany E, Hassan M, Zoheiry M. Effects of free and nanoparticulate curcumin on chemically induced liver carcinoma in an animal model. Arch Med Sci 2021;17:218-27. [PMID: 33488874 DOI: 10.5114/aoms.2020.93739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation. J Vasc Interv Radiol 2020;31:1475-1482.e2. [PMID: 32800663 DOI: 10.1016/j.jvir.2020.03.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Su B, Luo P, Yang Z, Yu P, Li Z, Yin P, Zhou L, Fan J, Huang X, Lin X, Qiao Y, Xu G. A novel analysis method for biomarker identification based on horizontal relationship: identifying potential biomarkers from large-scale hepatocellular carcinoma metabolomics data. Anal Bioanal Chem 2019;411:6377-86. [DOI: 10.1007/s00216-019-02011-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
28 Kimura Y, Kaneko R, Yano Y, Kamada K, Ikehara T, Nagai H, Sato Y, Igarashi Y. The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE. Asian Pac J Cancer Prev 2020;21:1797-805. [PMID: 32592380 DOI: 10.31557/APJCP.2020.21.6.1797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
30 Pocha C, Xie C. Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? Transl Gastroenterol Hepatol 2019;4:72. [PMID: 31728429 DOI: 10.21037/tgh.2019.09.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
31 Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.J Hepatocell Carcinoma. 2019;6:49-69. [PMID: 30788336 DOI: 10.2147/JHC.S186239] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
32 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol 2021;75:108-19. [PMID: 33548385 DOI: 10.1016/j.jhep.2021.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
33 Zhao Y, Wang N, Wu J, Zhang Q, Lin T, Yao Y, Chen Z, Wang M, Sheng L, Liu J, Song Q, Wang F, An X, Guo Y, Li X, Wu T, Liu AL. Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Oncol. 2021;11:582788. [PMID: 33868988 DOI: 10.3389/fonc.2021.582788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Dig Dis Sci 2019;64:632-42. [PMID: 30725292 DOI: 10.1007/s10620-019-05484-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
35 Muraoka M, Maekawa S, Katoh R, Komiyama Y, Nakakuki N, Takada H, Matsuda S, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamauchi K, Yamaguchi T, Nakayama Y, Inoue T, Enomoto N. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy. Hepatol Commun 2021;5:1927-38. [PMID: 34558819 DOI: 10.1002/hep4.1762] [Reference Citation Analysis]
36 Kim S, Yoon CJ, Cho JY, Han HS, Yoon YS, Lee HW, Lee JS, Kim M, Lee B, Ahn S. Comparative long-term outcomes of laparoscopic hepatectomy and radiofrequency ablation for hepatocellular carcinoma located in the anterolateral segments of the liver. J Hepatobiliary Pancreat Sci 2021. [PMID: 34689415 DOI: 10.1002/jhbp.1064] [Reference Citation Analysis]
37 Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, de Ledinghen V, Zoulim F, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Rep 2021;3:100298. [PMID: 34142073 DOI: 10.1016/j.jhepr.2021.100298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ren C, Ren X, Cao D, Zhao H, Zhai Z, Li H, Li Y, Fu X, He J, Zhao H. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma. FEBS Open Bio 2020;10:847-60. [PMID: 32160402 DOI: 10.1002/2211-5463.12836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Buranupakorn T, Thangsuk P, Patumanond J, Phinyo P. Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:992. [PMID: 33673534 DOI: 10.3390/cancers13050992] [Reference Citation Analysis]
41 Kang HJ, Kim H, Lee DH, Hur BY, Hwang YJ, Suh KS, Han JK. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology 2021;:204352. [PMID: 34227881 DOI: 10.1148/radiol.2021204352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
43 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Kim DW, Choi SH, Kim SY, Byun JH, Lee SS, Park SH, Kim KW. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 2020;14:1009-22. [DOI: 10.1007/s12072-020-10100-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
46 Tefera J, Revzin M, Chapiro J, Savic LJ, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation. J Clin Pathol. 2021;74:31-35. [PMID: 32430483 DOI: 10.1136/jclinpath-2020-206574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
47 Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K, Mitchell DG. CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 2019;44:1306-22. [PMID: 30671612 DOI: 10.1007/s00261-018-1868-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
48 Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:171. [PMID: 32185125 DOI: 10.3389/fonc.2020.00171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
49 Tsilimigras DI, Bagante F, Moris D, Hyer JM, Sahara K, Paredes AZ, Mehta R, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020;27:2321-31. [PMID: 32285278 DOI: 10.1245/s10434-020-08452-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
50 Spiliotis AE, Gäbelein G, Holländer S, Scherber PR, Glanemann M, Patel B. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. Radiol Oncol 2021;55:247-58. [PMID: 34167181 DOI: 10.2478/raon-2021-0030] [Reference Citation Analysis]
51 Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, Nguyen MH. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 2020;40:1052-1061. [PMID: 32086988 DOI: 10.1111/liv.14415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
53 Corma-Gómez A, Macías J, Lacalle-Remigio JR, Téllez F, Morano L, Rivero A, Serrano M, Ríos MJ, Vera-Méndez FJ, Alados JC, Real LM, Palacios R, Santos IL, Imatz A, Pineda JA. HIV infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis C infected-patients with advanced fibrosis. Clin Infect Dis 2020:ciaa1111. [PMID: 32766891 DOI: 10.1093/cid/ciaa1111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Lyu N, Kong Y, Li X, Guo N, Lai J, Li J, Zhao M. Effect and Safety of Prophylactic Parecoxib for Pain Control of Transarterial Chemoembolization in Liver Cancer: A Single-Center, Parallel-Group, Randomized Trial. J Am Coll Radiol 2021:S1546-1440(21)00838-3. [PMID: 34736908 DOI: 10.1016/j.jacr.2021.09.029] [Reference Citation Analysis]
55 Choi SH, Jeon SK, Lee SS, Lee JM, Hur BY, Kang HJ, Kim H, Park Y. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol 2021. [PMID: 34037829 DOI: 10.1007/s00330-021-07984-w] [Reference Citation Analysis]
56 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Tsilimigras DI, Bagante F, Sahara K, Moris D, Hyer JM, Wu L, Ratti F, Marques HP, Soubrane O, Paredes AZ, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. Ann Surg Oncol 2019;26:3693-700. [PMID: 31267302 DOI: 10.1245/s10434-019-07580-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 16.5] [Reference Citation Analysis]
58 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
59 Lee S, Kim YY, Shin J, Hwang SH, Roh YH, Chung YE, Choi JY. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. J Am Coll Radiol 2020;17:1199-206. [PMID: 32640250 DOI: 10.1016/j.jacr.2020.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
60 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 104.0] [Reference Citation Analysis]
61 Chen F, He L, Qiu L, Zhou Y, Li Z, Chen G, Xin F, Dong X, Xu H, Wang G, Liu J, Cai Z. Circular RNA CircEPB41L2 Functions as Tumor Suppressor in Hepatocellular Carcinoma Through Sponging miR-590-5p. Cancer Manag Res 2021;13:2969-81. [PMID: 33833580 DOI: 10.2147/CMAR.S291682] [Reference Citation Analysis]
62 Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK; Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer 2020;20:483. [PMID: 32471447 DOI: 10.1186/s12885-020-06806-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hu B, Zhong BY, Zhang L, Dai C, Li W, Shen J, Huang P, Zhang S, Li Z, Ni CF. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE. Cardiovasc Intervent Radiol 2020;43:1460-7. [PMID: 32500251 DOI: 10.1007/s00270-020-02501-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS One 2019;14:e0218136. [PMID: 31194789 DOI: 10.1371/journal.pone.0218136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol 2020;30:4150-63. [PMID: 32166493 DOI: 10.1007/s00330-020-06754-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
66 Chen K, Li Q, Zhao X, Zhang J, Ma H, Sun X, Yu Q, Zhang Y, Fang C, Nie L. Biocompatible melanin based theranostic agent for in vivo detection and ablation of orthotopic micro-hepatocellular carcinoma. Biomater Sci 2020;8:4322-33. [PMID: 32602480 DOI: 10.1039/d0bm00825g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ronot M, Purcell Y, Vilgrain V. Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. Dig Dis Sci 2019;64:934-50. [DOI: 10.1007/s10620-019-05547-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
68 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
69 Wang DC, Jang H, Kim TK. Characterization of Indeterminate Liver Lesions on CT and MRI With Contrast-Enhanced Ultrasound: What Is the Evidence? American Journal of Roentgenology 2020;214:1295-304. [DOI: 10.2214/ajr.19.21498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
70 Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 145.0] [Reference Citation Analysis]
71 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
72 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 70] [Article Influence: 38.5] [Reference Citation Analysis]
73 Wu TT, Cai J, Tian YH, Chen JF, Cheng ZL, Pu CS, Shi WZ, Suo XP, Wu XJ, Dou XW, Zhang KM. MTF2 Induces Epithelial-Mesenchymal Transition and Progression of Hepatocellular Carcinoma by Transcriptionally Activating Snail. Onco Targets Ther 2019;12:11207-20. [PMID: 31908487 DOI: 10.2147/OTT.S226119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
74 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]
75 Arora S, Harmath C, Catania R, Mandler A, Fowler KJ, Borhani AA. Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings. Abdom Radiol (NY) 2021;46:3698-707. [PMID: 34091729 DOI: 10.1007/s00261-021-03151-3] [Reference Citation Analysis]
76 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Vernuccio F, Cannella R, Choudhury KR, Meyer M, Furlan A, Marin D. Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression. Eur J Radiol 2020;128:109018. [PMID: 32388318 DOI: 10.1016/j.ejrad.2020.109018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Chen X, Zhang H, Ou S, Chen H. Von Hippel-Lindau gene single nucleotide polymorphism (rs1642742) may be related to the occurrence and metastasis of HBV-related hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27187. [PMID: 34477178 DOI: 10.1097/MD.0000000000027187] [Reference Citation Analysis]
79 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. mSystems. 2020;5. [PMID: 32546668 DOI: 10.1128/msystems.00153-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
81 Maida M, Sferrazza S, Savarino E, Ricciardiello L, Repici A, Morisco F, Furnari M, Fuccio L, Morreale GC, Vitello A, Burra P, Marchi S, Annibale B, Benedetti A, Alvaro D, Ianiro G; Italian Society of Gastroenterology (SIGE). Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. Dig Liver Dis 2020;52:808-15. [PMID: 32425733 DOI: 10.1016/j.dld.2020.05.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 27.0] [Reference Citation Analysis]
82 Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, Zhang J, Li J, Wong C, Wong C, Cheung RC, Yang HI, Nguyen MH. Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00069-0. [PMID: 33465482 DOI: 10.1016/j.cgh.2021.01.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Pinheiro PS, Medina HN, Callahan KE, Jones PD, Brown CP, Altekruse SF, McGlynn KA, Kobetz EN. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int 2020;40:1201-10. [PMID: 32087002 DOI: 10.1111/liv.14409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
84 Bhutiani N, O'brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, Mcmasters KM, Martin RC, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). HPB 2020;22:1330-8. [DOI: 10.1016/j.hpb.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Feng JK, Chen ZH, Sun JX, Wu JY, Guo WX, Shi J, Wei YG, Zhou JY, Zhang ZB, Yan ML, Cheng SQ. Concurrent bile duct resection versus concomitant thrombectomy for hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. Ann Transl Med 2021;9:457. [PMID: 33850854 DOI: 10.21037/atm-20-6449] [Reference Citation Analysis]
86 Hershberger CE, Rodarte AI, Siddiqi S, Moro A, Acevedo-Moreno LA, Brown JM, Allende DS, Aucejo F, Rotroff DM. Salivary Metabolites are Promising Non-Invasive Biomarkers of Hepatocellular Carcinoma and Chronic Liver Disease. Liver Cancer Int 2021;2:33-44. [PMID: 34541549 DOI: 10.1002/lci2.25] [Reference Citation Analysis]
87 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Mukund A, Ramalingam R, Anandpara KM, Patidar Y, Vijayaraghavan R, Sarin SK. Efficacy and safety of percutaneous microwave ablation for hepatocellular carcinomas <4 cm in difficult location. Br J Radiol 2020;93:20191025. [PMID: 32970472 DOI: 10.1259/bjr.20191025] [Reference Citation Analysis]
89 von Felden J. New systemic agents for hepatocellular carcinoma: an update 2020. Curr Opin Gastroenterol 2020;36:177-83. [PMID: 32101985 DOI: 10.1097/MOG.0000000000000626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
90 Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol 2020;11:613946. [PMID: 33488622 DOI: 10.3389/fimmu.2020.613946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
92 Aboughaleb IH, Matboli M, Shawky SM, El-Sharkawy YH. Integration of transcriptomes analysis with spectral signature of total RNA for generation of affordable remote sensing of Hepatocellular carcinoma in serum clinical specimens. Heliyon 2021;7:e06388. [PMID: 33748469 DOI: 10.1016/j.heliyon.2021.e06388] [Reference Citation Analysis]
93 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Ciurea AM, Vere CC, Schenker M, Gheonea IA, Streba L, Săndulescu LD, Mehedinţeanu AM, Gheonea DI. Evaluation of Hepatocellular Carcinoma Patients: Interim Analysis of Cases from a Tertiary Referral Center in Craiova, Romania. Curr Health Sci J 2021;47:10-5. [PMID: 34211741 DOI: 10.12865/CHSJ.47.01.02] [Reference Citation Analysis]
95 Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
96 Granata V, Grassi R, Fusco R, Belli A, Cutolo C, Pradella S, Grazzini G, La Porta M, Brunese MC, De Muzio F, Ottaiano A, Avallone A, Izzo F, Petrillo A. Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma. Infect Agent Cancer 2021;16:53. [PMID: 34281580 DOI: 10.1186/s13027-021-00393-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Cunha GM, Kwon H, Wolfson T, Gamst AC, Chung YE, Kim M, Kim SW, Sirlin CB, Fowler KJ. Examining LI-RADS recommendations: should observation size only be measured on non-arterial phases? Abdom Radiol 2020;45:3144-54. [DOI: 10.1007/s00261-020-02490-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Pagé G, Doblas S, Garteiser P, Van Beers BE. Editorial for "Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging". J Magn Reson Imaging 2021. [PMID: 34390605 DOI: 10.1002/jmri.27891] [Reference Citation Analysis]
99 Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B. Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Front Oncol 2020;10:570958. [PMID: 33102226 DOI: 10.3389/fonc.2020.570958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Wang Y, Shen J, Feng S, Liang R, Lai J, Li D, Peng B, Wang Z, Huang C, Kuang M. Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study. J Gastroenterol Hepatol 2020;35:2220-8. [PMID: 32246889 DOI: 10.1111/jgh.15060] [Reference Citation Analysis]
101 Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, Fragomeli V, Koay YC, Jackson M, O'Sullivan J, Weltman M, McCaughan G, El-Omar E, Zekry A. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun 2021;12:187. [PMID: 33420074 DOI: 10.1038/s41467-020-20422-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
102 Chu HH, Chun SY, Kim JH, Kim PH, Il Gwon D, Ko HK, Kim N. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol 2021;31:4232-42. [PMID: 33241523 DOI: 10.1007/s00330-020-07536-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
103 Lindquester WS, Dhangana R, Pinter J, Warhadpande S, Bandi R. Percutaneous ablation versus surgical ablation and resection of liver tumors: medicare volume and physician reimbursement trends from 2010 to 2018. Abdom Radiol (NY) 2021;46:4056-61. [PMID: 33772616 DOI: 10.1007/s00261-021-03054-3] [Reference Citation Analysis]
104 Ahrens TD, Bang-Christensen SR, Jørgensen AM, Løppke C, Spliid CB, Sand NT, Clausen TM, Salanti A, Agerbæk MØ. The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. Front Cell Dev Biol 2020;8:749. [PMID: 32984308 DOI: 10.3389/fcell.2020.00749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
105 Rimola J, Forner A, Sapena V, Llarch N, Darnell A, Díaz A, García-criado A, Bianchi L, Vilana R, Díaz-gonzález Á, Ayuso C, Bruix J, Reig M. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 2020;30:186-94. [DOI: 10.1007/s00330-019-06351-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
106 Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. Cancers (Basel). 2019;11. [PMID: 31370183 DOI: 10.3390/cancers11081084] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 22.5] [Reference Citation Analysis]
107 Khan AA, Hadi YB, Thompson JM, Kupec JT. Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. BMJ Open Gastroenterol 2020;7:e000394. [PMID: 32398242 DOI: 10.1136/bmjgast-2020-000394] [Reference Citation Analysis]
108 Li Q, Song T. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Front Oncol 2021;11:633033. [PMID: 34631511 DOI: 10.3389/fonc.2021.633033] [Reference Citation Analysis]
109 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
110 Sheng R, Huang J, Zhang W, Jin K, Yang L, Chong H, Fan J, Zhou J, Wu D, Zeng M. A Semi-Automatic Step-by-Step Expert-Guided LI-RADS Grading System Based on Gadoxetic Acid-Enhanced MRI. J Hepatocell Carcinoma 2021;8:671-83. [PMID: 34235105 DOI: 10.2147/JHC.S316385] [Reference Citation Analysis]
111 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
112 Feng Y, Wu H, Huang DQ, Xu C, Zheng H, Maeda M, Zhao X, Wang L, Xiao F, Lv H, Liu T, Qi J, Li J, Zhong N, Wang C, Feng H, Liang B, Ren W, Qin C, Nguyen MH, Zhu Q. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.Eur Radiol. 2020;30:6357-6368. [PMID: 32529568 DOI: 10.1007/s00330-020-06990-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
113 Ye Z, Deng Z, Jiang S, Wang T, Liu L, Jiang K, Zhang Y. Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy. Cardiovasc Intervent Radiol 2021;44:1394-402. [PMID: 33948697 DOI: 10.1007/s00270-021-02846-w] [Reference Citation Analysis]
114 Liu X, Zhang H, Zhou P, Yu Y, Zhang H, Chen L, Gong J, Liu Z. CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells. Oncol Rep 2021;45:79. [PMID: 33786634 DOI: 10.3892/or.2021.8030] [Reference Citation Analysis]
115 Li Q, Zhang L, Hou ZH, Zhao DX, Li JB, Zhang S, Yin Y, Ni CF, Chen T. High Visceral Adipose Tissue Density Correlates With Unfavorable Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Front Cell Dev Biol 2021;9:710104. [PMID: 34568324 DOI: 10.3389/fcell.2021.710104] [Reference Citation Analysis]
116 Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
117 von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69:2025-2034. [PMID: 32883873 DOI: 10.1136/gutjnl-2019-320282] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
118 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
119 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
120 Ivanics T, Nelson W, Patel MS, Claasen MPAW, Lau L, Gorgen A, Abreu P, Goldenberg A, Erdman L, Sapisochin G. The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. Liver Transpl 2021. [PMID: 34626159 DOI: 10.1002/lt.26332] [Reference Citation Analysis]
121 Lim J, Kim HI, Kim E, Kim J, An J, Chang S, Kim SO, Lee HC, Lee YS, Shim JH. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer 2021;21:11. [PMID: 33402105 DOI: 10.1186/s12885-020-07708-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Zhu XL, Wen L, Ni CF. Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Mol Biosci 2021;8:618050. [PMID: 34095216 DOI: 10.3389/fmolb.2021.618050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Cha DI, Jang KM, Kim SH, Kim YK, Kim H, Ahn SH. Preoperative Prediction for Early Recurrence Can Be as Accurate as Postoperative Assessment in Single Hepatocellular Carcinoma Patients. Korean J Radiol 2020;21:402-12. [PMID: 32193888 DOI: 10.3348/kjr.2019.0538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
124 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 345.0] [Reference Citation Analysis]
125 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
126 Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, Huang P, Fang T, Yang B, Xia J. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18:306. [PMID: 32762721 DOI: 10.1186/s12967-020-02469-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
127 Liu Q, You N, Li J, Wu K, Peng X, Wang Z, Wang L, Zhu Y, Zheng L. Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2021;11:694409. [PMID: 34737945 DOI: 10.3389/fonc.2021.694409] [Reference Citation Analysis]
128 Zhao H, Wang M, Xiong X, Liu Y, Chen X. Simultaneous fluorescent detection of multiplexed miRNA of liver cancer based on DNA tetrahedron nanotags. Talanta 2020;210:120677. [DOI: 10.1016/j.talanta.2019.120677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
129 Nie G, Peng D, Li B, Lu J, Cai Y, Xiong X, Cheng N. Diagnostic Accuracy of Serum/Plasma Circular RNAs and the Combination of Circular RNAs and α-Fetoprotein for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:722208. [PMID: 34659344 DOI: 10.3389/fgene.2021.722208] [Reference Citation Analysis]
130 von Felden J, Garcia-Lezana T, Dogra N, Gonzalez-Kozlova E, Ahsen ME, Craig A, Gifford S, Wunsch B, Smith JT, Kim S, Diaz JEL, Chen X, Labgaa I, Haber P, Olsen R, Han D, Restrepo P, D'Avola D, Hernandez-Meza G, Allette K, Sebra R, Saberi B, Tabrizian P, Asgharpour A, Dieterich D, Llovet JM, Cordon-Cardo C, Tewari A, Schwartz M, Stolovitzky G, Losic B, Villanueva A. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut 2021:gutjnl-2021-325036. [PMID: 34321221 DOI: 10.1136/gutjnl-2021-325036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Yen YH, Cheng YF, Wang JH, Lin CC, Chen CH, Wang CC. Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS One 2021;16:e0249194. [PMID: 33765059 DOI: 10.1371/journal.pone.0249194] [Reference Citation Analysis]
132 Lew M, Hissong EM, Westerhoff MA, Lamps LW. Optimizing small liver biopsy specimens: a combined cytopathology and surgical pathology perspective. J Am Soc Cytopathol 2020;9:405-21. [PMID: 32641246 DOI: 10.1016/j.jasc.2020.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Brunsing RL, Fowler KJ, Yokoo T, Cunha GM, Sirlin CB, Marks RM. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res 2020;6:59. [PMID: 33381651 DOI: 10.20517/2394-5079.2020.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
134 Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J, Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, Kumada H. Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clin J Gastroenterol 2020;13:1225-32. [PMID: 32651870 DOI: 10.1007/s12328-020-01180-x] [Reference Citation Analysis]
135 Sultan A, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2020;14:1007-11. [PMID: 32730120 DOI: 10.1080/17474124.2020.1802246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
137 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]
138 Chen HY, Lu SN, Hung CH, Wang JH, Chen CH, Yen YH, Kuo YH, Kee KM. Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS One 2020;15:e0242113. [PMID: 33170894 DOI: 10.1371/journal.pone.0242113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
139 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
140 Feng Z, Zhao H, Guan S, Wang W, Rong P. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis. Liver Int 2021;41:1117-28. [DOI: 10.1111/liv.14850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
141 Clarke CGD, Albazaz R, Smith CR, Rowe I, Treanor D, Wyatt JI, Sheridan MB, Guthrie JA. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clin Radiol 2021;76:333-41. [PMID: 33461746 DOI: 10.1016/j.crad.2020.12.007] [Reference Citation Analysis]
142 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
143 Lee HW, Lee JI, Kim S, Kim S, Chang HY, Lee KS. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. BMC Gastroenterol 2020;20:113. [PMID: 32305059 DOI: 10.1186/s12876-020-01236-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
144 Hermann A, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; For the SARAH Trial Group. Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study. Radiology 2020;296:673-84. [DOI: 10.1148/radiol.2020191606] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 24.0] [Reference Citation Analysis]
145 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
146 Tagliamonte M, Mauriello A, Cavalluzzo B, Ragone C, Manolio C, Petrizzo A, Buonaguro L. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Lett. 2020;473:25-32. [PMID: 31875523 DOI: 10.1016/j.canlet.2019.12.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
147 Cunha GM, Tamayo-murillo DE, Fowler KJ. LI-RADS and transplantation: challenges and controversies. Abdom Radiol 2021;46:29-42. [DOI: 10.1007/s00261-019-02311-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Bai S, Yang P, Xie Z, Li J, Lei Z, Xia Y, Qian G, Zhang B, Pawlik TM, Lau WY, Shen F. Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2021;28:8174-85. [PMID: 34409542 DOI: 10.1245/s10434-021-09901-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1:4-13. [PMID: 32319693 DOI: 10.1002/hep.31288] [Cited by in Crossref: 61] [Cited by in F6Publishing: 77] [Article Influence: 61.0] [Reference Citation Analysis]
150 Lee SY, Ou HY, Yu CY, Huang TL, Tsang LL, Cheng YF. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter? Diagn Interv Radiol 2020;26:230-5. [PMID: 32352922 DOI: 10.5152/dir.2019.19261] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
153 Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y, Ogawa C, Akazawa K. B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. Liver Cancer 2019;8:271-80. [PMID: 31602370 DOI: 10.1159/000501082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
154 Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Liver resection in elderly patients with hepatocellular carcinoma: age does matter. Updates Surg 2021;73:1371-80. [PMID: 33687694 DOI: 10.1007/s13304-021-01021-7] [Reference Citation Analysis]
155 Huang PH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YS, Chao M, Lin CL, Yeh CT. The Defective Allele of Aldehyde Dehydrogenase 2 Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:5735-43. [PMID: 31737110 DOI: 10.7150/jca.33221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Reference Citation Analysis]
157 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
158 Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park J. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology 2021;74:603-12. [DOI: 10.1016/j.jhep.2020.09.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
159 Huang J, Huang W, Guo Y, Cai M, Zhou J, Lin L, Zhu K. Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma. Front Oncol 2021;11:638428. [PMID: 34123790 DOI: 10.3389/fonc.2021.638428] [Reference Citation Analysis]
160 Zhang Y, Wang J, Li H, Zheng T, Jiang H, Li M, Song B. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Ann Transl Med 2020;8:388. [PMID: 32355832 DOI: 10.21037/atm.2020.03.120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
161 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
162 Kong J, Shen S, Wang W. Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: A systematic review and meta-analysis. J Surg Oncol 2019;119:964-73. [PMID: 30775785 DOI: 10.1002/jso.25392] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
163 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:953-60. [PMID: 32376182 DOI: 10.1016/j.jvir.2019.12.809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 von Felden J, Craig AJ, Villanueva A. The Impact of Translational Research in Hepatology. Clin Liver Dis (Hoboken) 2019;13:29-33. [PMID: 31168363 DOI: 10.1002/cld.805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 41.0] [Reference Citation Analysis]
166 Degrauwe N, Hocquelet A, Digklia A, Schaefer N, Denys A, Duran R. Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures. Front Pharmacol 2019;10:450. [PMID: 31143114 DOI: 10.3389/fphar.2019.00450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
167 Lockart I, Hajarizadeh B, Buckley N, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol 2021. [PMID: 34520088 DOI: 10.1111/jgh.15687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Nilles KM, Levitsky J. Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. Semin Liver Dis 2021;41:308-20. [PMID: 34130337 DOI: 10.1055/s-0041-1729969] [Reference Citation Analysis]
169 Li JR, Wu MJ, Wang T, Tian M, Zhou G, Liu QX, Xiang XH, Zhang YQ. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. Abdom Radiol (NY) 2021;46:1967-76. [PMID: 33386450 DOI: 10.1007/s00261-020-02897-6] [Reference Citation Analysis]
170 Kuo FY, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. J Surg Oncol 2021;123:222-35. [PMID: 33084068 DOI: 10.1002/jso.26260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Cannella R, Fowler KJ, Borhani AA, Minervini MI, Heller M, Furlan A. Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience. Abdom Radiol 2019;44:43-53. [DOI: 10.1007/s00261-018-1720-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
172 Zhu W, Xu J, Chen Z, Jiang J. Analyzing Roles of NUSAP1 From Clinical, Molecular Mechanism and Immune Perspectives in Hepatocellular Carcinoma. Front Genet 2021;12:689159. [PMID: 34354737 DOI: 10.3389/fgene.2021.689159] [Reference Citation Analysis]
173 Wallace MC, Samuelson S, Khoo T, Ooi J, Tibballs J, Ferguson J, Preen DB, Knuiman M, Garas G, MacQuillan G, Adams LA, Jeffrey GP. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with Yttrium-90 resin microsphere radioembolization. J Gastroenterol Hepatol 2020;35:1945-52. [PMID: 32036614 DOI: 10.1111/jgh.15008] [Reference Citation Analysis]
174 Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer 2021;10:275-84. [PMID: 34239813 DOI: 10.1159/000515553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Hwang SH, Hong SB, Han K, Seo N, Choi JY, Lee JH, Park S, Lim YS, Kim DY, Kim SY, Park MS. A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features. J Magn Reson Imaging 2021. [PMID: 34668595 DOI: 10.1002/jmri.27962] [Reference Citation Analysis]
176 Byrd K, Alqahtani S, Yopp AC, Singal AG. Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. Semin Liver Dis 2021;41:1-8. [PMID: 33764480 DOI: 10.1055/s-0040-1719178] [Reference Citation Analysis]
177 Zhao H, Meng Y, Zhai X, Cheng B, Yu S, Yao M, Yin H, Wan X, Yang Y, Liu H, Shen F, Ling C. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study. Journal of Integrative Medicine 2020;18:319-25. [DOI: 10.1016/j.joim.2020.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
178 Kabir T, Syn NL, Tan ZZX, Tan HJ, Yen C, Koh YX, Kam JH, Teo JY, Lee SY, Cheow PC, Chow PKH, Chung AYF, Ooi LL, Chan CY, Goh BKP. Predictors of post-operative complications after surgical resection of hepatocellular carcinoma and their prognostic effects on outcome and survival: A propensity-score matched and structural equation modelling study. Eur J Surg Oncol 2020;46:1756-65. [PMID: 32345496 DOI: 10.1016/j.ejso.2020.03.219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
179 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Reference Citation Analysis]
180 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Bejjani A, Finn RS. The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:51-5. [PMID: 31508220 DOI: 10.1002/cld.815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
183 Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31297-0. [PMID: 32961340 DOI: 10.1016/j.cgh.2020.09.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
184 Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2021:S1590-8658(21)00766-0. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Reference Citation Analysis]
185 Wen L, Weng S, Yan C, Ye R, Zhu Y, Zhou L, Gao L, Li Y. A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation. Front Oncol 2021;11:657039. [PMID: 34026632 DOI: 10.3389/fonc.2021.657039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Yang JD, Patel T. Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. Hepatology 2019;69:1855-7. [PMID: 30556586 DOI: 10.1002/hep.30468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
187 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
188 Shao YY, Wang SY, Lin SM; Diagnosis Group,., Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 2021;120:1051-60. [PMID: 33199101 DOI: 10.1016/j.jfma.2020.10.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
189 Jepsen P, West J. We need stronger evidence for (or against) hepatocellular carcinoma surveillance. J Hepatol 2021;74:1234-9. [PMID: 33465402 DOI: 10.1016/j.jhep.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
190 Tsilimigras DI, Sahara K, Moris D, Hyer JM, Paredes AZ, Bagante F, Merath K, Farooq AS, Ratti F, Marques HP, Soubrane O, Azoulay D, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. J Gastrointest Surg 2020;24:1552-60. [DOI: 10.1007/s11605-019-04275-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
191 El-Khazragy N, Elshimy AA, Hassan SS, Shaaban MH, Bayoumi AH, El Magdoub HM, Ghozy S, Gaballah A, Aboelhussein MM, Abou Gabal HH, Bannunah AM, Mansy AE. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy. Mol Carcinog 2020;59:1382-91. [PMID: 33074585 DOI: 10.1002/mc.23263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Beal EW, Mehta R, Merath K, Tsilimigras DI, Hyer JM, Paredes A, Dillhoff ME, Cloyd J, Ejaz A, Pawlik TM. Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume. J Gastrointest Surg 2019;23:1425-34. [DOI: 10.1007/s11605-019-04233-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
193 Byun J, Kim SY, Kim JH, Kim MJ, Yoo C, Shim JH, Lee SS. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging. Acta Radiol 2020;:284185120971844. [PMID: 33197329 DOI: 10.1177/0284185120971844] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Choi MH, Choi JI, Lee YJ. Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). Ultrasonography 2021;40:237-47. [PMID: 32660211 DOI: 10.14366/usg.20052] [Reference Citation Analysis]
195 Kang JH, Choi SH, Lee JS, Kim DW, Jang JK. Inter-reader reliability of contrast-enhanced ultrasound Liver Imaging Reporting and Data System: a meta-analysis. Abdom Radiol (NY) 2021. [PMID: 34156509 DOI: 10.1007/s00261-021-03169-7] [Reference Citation Analysis]
196 Voutsadakis IA. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. Hepatobiliary & Pancreatic Diseases International 2019;18:505-10. [DOI: 10.1016/j.hbpd.2019.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
197 Samuel R, Bilal M, Nawgiri R, Merwat S, Parupudi S, Guturu P. Recurrence of hepatocellular carcinoma at the porta-hepatis following liver transplantation diagnosed on EUS-FNA. Clin J Gastroenterol 2019;12:336-40. [DOI: 10.1007/s12328-019-00934-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
198 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Mahfouz M, Nguyen H, Tu J, Diaz CR, Anjan S, Brown S, Bosire K, Carrasquillo O, Martin P, Jones PD. Knowledge and Perceptions of Hepatitis B and Hepatocellular Carcinoma Screening Guidelines Among Trainees: A Tale of Three Centers. Dig Dis Sci 2020;65:2551-61. [PMID: 31813133 DOI: 10.1007/s10620-019-05980-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Bashir MR, Chernyak V. Can MRI Features of Combined Hepatocellular Carcinoma-Intrahepatic Cholangiogarcinoma Help Predict Tumor Behavior Better than Histologic Findings? Radiology 2019;290:398-9. [PMID: 30422087 DOI: 10.1148/radiol.2018182408] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Yim SY, Lee JS. Genomic Perspective on Mouse Liver Cancer Models. Cancers (Basel) 2019;11:E1648. [PMID: 31731480 DOI: 10.3390/cancers11111648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
202 Moldogazieva NT, Zavadskiy SP, Sologova SS, Mokhosoev IM, Terentiev AA. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn 2021;:1-18. [PMID: 34582293 DOI: 10.1080/14737159.2021.1987217] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
203 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Han B, Ding H, Zhao S, Zhang Y, Wang J, Zhang Y, Gu J. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. Front Oncol 2020;10:562103. [PMID: 33365268 DOI: 10.3389/fonc.2020.562103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
205 Zhou W, Fang D, He Y, Wei J. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. J Gastrointest Oncol 2021;12:1117-31. [PMID: 34295561 DOI: 10.21037/jgo-21-259] [Reference Citation Analysis]
206 Viganò L, Lleo A, Muglia R, Gennaro N, Samà L, Colapietro F, Roncalli M, Aghemo A, Chiti A, Di Tommaso L, Solbiati L, Colombo M, Torzilli G. Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. Updates Surg 2020;72:413-21. [PMID: 32323164 DOI: 10.1007/s13304-020-00750-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kim SA, Cho EJ, Lee S, Cho YY, Kim B, Yoon JH, Park T. Changes in serum fibronectin levels predict tumor recurrence in patients with early hepatocellular carcinoma after curative treatment. Sci Rep 2020;10:21313. [PMID: 33277619 DOI: 10.1038/s41598-020-78440-w] [Reference Citation Analysis]
208 Kang JH, Choi SH, Lee JS, Kim KW, Kim SY, Lee SS, Byun JH. Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis. Eur Radiol 2021;31:6856-67. [PMID: 33713172 DOI: 10.1007/s00330-021-07815-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol 2021;11:641195. [PMID: 33912456 DOI: 10.3389/fonc.2021.641195] [Reference Citation Analysis]
210 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
211 Serenari M, Cappelli A, Cucchetti A, Mosconi C, Strigari L, Monari F, Ravaioli M, Rizzini EL, Fanti S, Golfieri R, Cescon M. Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. Liver Transpl 2021. [PMID: 34355489 DOI: 10.1002/lt.26257] [Reference Citation Analysis]
212 Johnston MP, Patel J, Byrne CD. Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis-implications for surveillance and future pharmacotherapy. Hepatobiliary Surg Nutr 2020;9:230-4. [PMID: 32355688 DOI: 10.21037/hbsn.2019.10.09] [Reference Citation Analysis]
213 Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E, Roviello G. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34289756 DOI: 10.1080/17512433.2021.1958674] [Reference Citation Analysis]
214 Choi JM, Yu JS, Cho ES, Kim JH, Chung JJ. Texture Analysis of Hepatocellular Carcinoma on Magnetic Resonance Imaging: Assessment for Performance in Predicting Histopathologic Grade. J Comput Assist Tomogr 2020;44:901-10. [PMID: 32976263 DOI: 10.1097/RCT.0000000000001087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 Singh MK, Roy R, Shetty V, Goja S. Hepatocellular carcinoma with atrial tumor thrombus presenting as myxoma: Resection under cardiopulmonary bypass. Ann Hepatobiliary Pancreat Surg 2020;24:518-21. [PMID: 33234756 DOI: 10.14701/ahbps.2020.24.4.518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Singh A, Shafi S, Upadhyay T, Najmi AK, Kohli K, Pottoo FH. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Curr Top Med Chem 2020;20:1839-54. [PMID: 32579503 DOI: 10.2174/1568026620666200624161801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
218 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
219 Ruff SM, Rothermel LD, Diggs LP, Wach MM, Ayabe RI, Martin SP, Boulware D, Anaya D, Davis JL, Mullinax JE, Hernandez JM. Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 2020;22:1004-10. [PMID: 31734237 DOI: 10.1016/j.hpb.2019.10.1531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
220 Lee J, Kim GA, Kim HJ, Cho S, Ko MJ, Lim YS. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. J Viral Hepat 2021;28:1150-9. [PMID: 33934466 DOI: 10.1111/jvh.13530] [Reference Citation Analysis]
221 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
222 Kim DH, Choi SH, Lee JS, Choi JI. Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis. Abdom Radiol (NY) 2021. [PMID: 34633497 DOI: 10.1007/s00261-021-03297-0] [Reference Citation Analysis]
223 Rimola J, Darnell A, Belmonte E, Sapena V, Caparroz C, Llarch N, Reig M, Forner A, Bruix J, Ayuso C. Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. Eur Radiol 2020;30:6694-701. [DOI: 10.1007/s00330-020-07039-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, Yokoyama Y, Oishi T, Maeda M, Kimura T, Kotoh Y, Sasaki R, Miyaji T, Oono T, Aibe Y, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. Cancers (Basel) 2020;12:E779. [PMID: 32218295 DOI: 10.3390/cancers12040779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
226 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
227 Zhao Y, Fu T, Meng G, Qiao F, Hou Y, Liu Y, Yang J. Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line. Anticancer Agents Med Chem 2020;20:2293-303. [PMID: 32748761 DOI: 10.2174/1871520620999200730170844] [Reference Citation Analysis]
228 Lee S, Song GW, Kim KW, Kwon JH, Lee SG. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes. Transplant Proc 2021;53:92-7. [PMID: 33288309 DOI: 10.1016/j.transproceed.2020.10.012] [Reference Citation Analysis]
229 Kim DH, Choi SH, Byun JH, Kang JH, Lim YS, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 2019;71:534-42. [PMID: 31108157 DOI: 10.1016/j.jhep.2019.05.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
230 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Reference Citation Analysis]
231 Yataco ML, Bowman AW, Keaveny AP. Management of the Incidental Liver Lesion. Am J Gastroenterol 2021;116:855-61. [PMID: 33298700 DOI: 10.14309/ajg.0000000000001089] [Reference Citation Analysis]
232 Gadsden MM, Kaplan DE. Multidisciplinary Approach to HCC Management: How Can This Be Done? Dig Dis Sci. 2019;64:968-975. [PMID: 30887152 DOI: 10.1007/s10620-019-05593-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
233 Yamashita Y, Joshita S, Kobayashi H, Wakabayashi SI, Sugiura A, Yamazaki T, Umemura T. Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. Medicina (Kaunas) 2021;57:280. [PMID: 33803501 DOI: 10.3390/medicina57030280] [Reference Citation Analysis]
234 Lee S, Kim KW, Song GW, Kwon JH, Hwang S, Kim KH, Ahn CS, Moon DB, Park GC, Lee SG. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2020;9:721-33. [PMID: 33442541 DOI: 10.1159/000507887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Ohshiro K, Chen J, Srivastav J, Mishra L, Mishra B. Alterations in TGF-β signaling leads to high HMGA2 levels potentially through modulation of PJA1/SMAD3 in HCC cells. Genes Cancer 2020;11:43-52. [PMID: 32577156 DOI: 10.18632/genesandcancer.199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
236 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 49.0] [Reference Citation Analysis]
237 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
238 Pelizzaro F, Penzo B, Peserico G, Imondi A, Sartori A, Vitale A, Cillo U, Giannini EG, Forgione A, Ludovico Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Giuseppe Foschi F, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Monofocal hepatocellular carcinoma: How much does size matter? Liver Int 2021;41:396-407. [PMID: 33155401 DOI: 10.1111/liv.14718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 27.0] [Reference Citation Analysis]
241 Ye F, Huang W, Xue Y, Tang E, Wang M, Shi F, Wei D, Han Y, Chen P, Zhang X, Yu D. Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. J Hepatocell Carcinoma 2021;8:285-300. [PMID: 33948441 DOI: 10.2147/JHC.S306966] [Reference Citation Analysis]
242 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, Mckenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol 2019;44:549-58. [DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
243 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 26.0] [Reference Citation Analysis]
244 Yang M, Parikh ND, Liu H, Wu E, Rao H, Feng B, Lin A, Wei L, Lok AS. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. Sci Rep. 2020;10:20922. [PMID: 33262356 DOI: 10.1038/s41598-020-77515-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
245 Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, Kim JK. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol 2021;216:1566-73. [PMID: 33852336 DOI: 10.2214/AJR.20.23213] [Reference Citation Analysis]
246 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
247 Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, Cho SB, Jeong YY. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:55-64. [PMID: 31646378 DOI: 10.1007/s00270-019-02349-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
248 Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 2021;70:401-7. [PMID: 32398224 DOI: 10.1136/gutjnl-2020-321040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
249 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma: Does the Background Liver With or Without Cirrhosis Matter? Am J Clin Pathol 2021:aqab125. [PMID: 34542582 DOI: 10.1093/ajcp/aqab125] [Reference Citation Analysis]
251 Okeke E, Mark Davwar P, Mullen B, Duguru M, Agbaji O, Sagay A, Murphy R, Hawkins C. The impact of HIV on hepatocellular cancer survival in Nigeria. Trop Med Int Health 2021;26:335-42. [PMID: 33244817 DOI: 10.1111/tmi.13532] [Reference Citation Analysis]
252 Kim SS, Eun JW, Choi JH, Woo HG, Cho HJ, Ahn HR, Suh CW, Baek GO, Cho SW, Cheong JY. MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma. Sci Rep. 2020;10:17862. [PMID: 33082400 DOI: 10.1038/s41598-020-74494-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
253 Wang C, Ding ZW, Zheng CG, Wang S, Li ZH, Zhang ZM, Pan J, Wang J, Yang C. COCH predicts survival and adjuvant TACE response in patients with HCC. Oncol Lett 2021;21:275. [PMID: 33732351 DOI: 10.3892/ol.2021.12536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Patacsil SJ, Noor M, Leyva A. A Review of Benign Hepatic Tumors and Their Imaging Characteristics. Cureus 2020;12:e6813. [PMID: 32140369 DOI: 10.7759/cureus.6813] [Reference Citation Analysis]
256 Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Wang JH, Yen YH. Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center. PLoS One 2020;15:e0230897. [PMID: 32218593 DOI: 10.1371/journal.pone.0230897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 Fu S, Wei J, Zhang J, Dong D, Song J, Li Y, Duan C, Zhang S, Li X, Gu D, Chen X, Hao X, He X, Yan J, Liu Z, Tian J, Lu L. Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study. Clin Transl Gastroenterol. 2019;10:e00070. [PMID: 31373932 DOI: 10.14309/ctg.0000000000000070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
258 Hwang JA, Min JH, Kang TW, Jeong WK, Kim YK, Ko SE, Choi SY. Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. Eur Radiol 2021. [PMID: 33856517 DOI: 10.1007/s00330-021-07897-8] [Reference Citation Analysis]
259 Deng M, Fang L, Li SH, Zhao RC, Mei J, Zou JW, Wei W, Guo RP. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis 2021;36:369-79. [PMID: 34467992 DOI: 10.1093/mutage/geab032] [Reference Citation Analysis]
260 Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology 2020;72:1819-37. [PMID: 32740969 DOI: 10.1002/hep.31491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
261 Rosenblatt R, Verna EC. COVID 19: Management of Decompensated Cirrhosis and Liver Transplant Recipients. Clin Liver Dis (Hoboken). 2020;15:200-203. [PMID: 32537136 DOI: 10.1002/cld.968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
262 Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. Cancer Med 2020;9:3057-69. [PMID: 32150664 DOI: 10.1002/cam4.2968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
263 Wu H, Liu TT, Feng YM, Xie XY, Su XN, Qi JN, Zhu Q, Qin CY. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus‐related hepatocellular carcinoma after hepatectomy. J Dig Dis 2020;21:650-63. [DOI: 10.1111/1751-2980.12941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Zhao Q, Xu Y, Yuan D, Yang J, Wang Y, Shen G, Huang X. Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study. Dis Markers 2021;2021:9958909. [PMID: 34394775 DOI: 10.1155/2021/9958909] [Reference Citation Analysis]
265 Choi WM, Kim JY, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Yoo C, Ryu MH, Ryoo BY, Kim KM. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int 2021;41:2189-99. [PMID: 33966338 DOI: 10.1111/liv.14932] [Reference Citation Analysis]
266 Lee CW, Yu MC, Wang CC, Lee WC, Tsai HI, Kuan FC, Chen CW, Hsieh YC, Chen HY. Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study. World J Gastrointest Surg 2021; 13(5): 476-492 [PMID: 34122737 DOI: 10.4240/wjgs.v13.i5.476] [Reference Citation Analysis]
267 Li CL, Ho MC, Lin YY, Tzeng ST, Chen YJ, Pai HY, Wang YC, Chen CL, Lee YH, Chen DS, Yeh SH, Chen PJ. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. Hepatology 2020;72:2063-76. [PMID: 32171027 DOI: 10.1002/hep.31230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
268 Di Sandro S, Benuzzi L, Lauterio A, Botta F, De Carlis R, Najjar M, Centonze L, Danieli M, Pezzoli I, Rampoldi A, Bagnardi V, De Carlis L. Single Hepatocellular Carcinoma approached by curative-intent treatment: A propensity score analysis comparing radiofrequency ablation and liver resection. European Journal of Surgical Oncology 2019;45:1691-9. [DOI: 10.1016/j.ejso.2019.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
269 Ma X, Mo M, Tan HJJ, Tan C, Zeng X, Zhang G, Huang D, Liang J, Liu S, Qiu X. LINC02499, a novel liver-specific long non-coding RNA with potential diagnostic and prognostic value, inhibits hepatocellular carcinoma cell proliferation, migration, and invasion. Hepatol Res 2020;50:726-40. [PMID: 32039538 DOI: 10.1111/hepr.13491] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
270 Feng Z, Li H, Zhao H, Jiang Y, Liu Q, Chen Q, Wang W, Rong P. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. Radiology 2021;300:219-29. [PMID: 33973839 DOI: 10.1148/radiol.2021203614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Shinkawa H, Tanaka S, Takemura S, Amano R, Kimura K, Nishioka T, Miyazaki T, Kubo S. Predictive Value of the Age-Adjusted Charlson Comorbidity Index for Outcomes After Hepatic Resection of Hepatocellular Carcinoma. World J Surg 2020;44:3901-14. [PMID: 32651603 DOI: 10.1007/s00268-020-05686-w] [Reference Citation Analysis]
272 Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzáles F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. AJR Am J Roentgenol 2019;213:W57-65. [PMID: 31039012 DOI: 10.2214/AJR.18.20979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
273 De Luca E, Marino D, Di Maio M. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. Cancer Manag Res 2020;12:3721-9. [PMID: 32547208 DOI: 10.2147/CMAR.S216220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
274 Zhang Z, Zhu J, Huang Y, Li W, Cheng H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol 2018;13:85. [PMID: 30390677 DOI: 10.1186/s13000-018-0763-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
275 Patel N, Maher J, Lie X, Gwaltney C, Barzi A, Karwal M, Macarulla T, Sun HC, Trojan J, Meyers O, Workman C, Morgan S, Negro A, Cohen G. Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res 2021. [PMID: 34115280 DOI: 10.1007/s11136-021-02903-4] [Reference Citation Analysis]
276 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
277 Carbonell G, Taouli B. Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. Magn Reson Imaging Clin N Am 2021;29:321-7. [PMID: 34243920 DOI: 10.1016/j.mric.2021.05.003] [Reference Citation Analysis]
278 Choi J, Yoo S, Lim YS. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology 2021;73:2155-66. [PMID: 33131063 DOI: 10.1002/hep.31610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Lai Q, Vitale A. BCLC staging system and liver transplantation: From a stage to a therapeutic hierarchy. Hepatobiliary Pancreat Dis Int 2021;20:4-5. [PMID: 33358081 DOI: 10.1016/j.hbpd.2020.12.014] [Reference Citation Analysis]
280 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
281 Lima PH, Fan B, Bérubé J, Cerny M, Olivié D, Giard JM, Beauchemin C, Tang A. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol 2019;213:17-25. [PMID: 30995098 DOI: 10.2214/AJR.18.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
282 Aliyari Ghasabeh M, Shaghaghi M, Pandey A, Ameli S, Ambale Venkatesh B, Jacob A, Pandey P, Hazhirkarzar B, Luo Y, Rezvani Habibabadi R, Khoshpouri P, Ghadimi M, Kamel IR. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). Eur Radiol 2021;31:1630-41. [PMID: 32910233 DOI: 10.1007/s00330-020-07251-4] [Reference Citation Analysis]
283 Lim K, Kwon H, Cho J. Inter-reader agreement and imaging-pathology correlation of the LI-RADS M on gadoxetic acid-enhanced magnetic resonance imaging: efforts to improve diagnostic performance. Abdom Radiol (NY) 2020;45:2430-9. [PMID: 32008112 DOI: 10.1007/s00261-020-02421-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Qiu L, Huang Y, Li Z, Dong X, Chen G, Xu H, Zeng Y, Cai Z, Liu X, Liu J. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol 2019;13:441-55. [PMID: 30537115 DOI: 10.1002/1878-0261.12424] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 24.5] [Reference Citation Analysis]
285 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Agyemang AO, Mensah MLK, Yamile RC, Ocloo A, Appiah AA, Mensah AY, Thomford KP. Clinical Evaluation of the Safety and Effectiveness of Heptonica: A Ghanaian Hepatorestorative Polyherbal Product. Evid Based Complement Alternat Med 2020;2020:9596182. [PMID: 32655671 DOI: 10.1155/2020/9596182] [Reference Citation Analysis]
287 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
288 Zou J, Li S, Wang Q, Mei J, Lu L, Lin W, Wen Y, Li Y, Wei W, Guo R. Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study. Cancer Med 2021;10:3274-87. [PMID: 33932132 DOI: 10.1002/cam4.3894] [Reference Citation Analysis]
289 Soloff EV, Desai N, Busey JM, Koprowicz KM, Shuman WP. Feasibility of wide detector three-pass arterial phase liver CT in patients with cirrhosis: timing of hyperenhancing lesion peak conspicuity. Abdom Radiol 2020;45:2370-7. [DOI: 10.1007/s00261-020-02539-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Ballotin VR, Bigarella LG, Soldera J, Soldera J. Deep learning applied to the imaging diagnosis of hepatocellular carcinoma. Artif Intell Gastrointest Endosc 2021; 2(4): 127-135 [DOI: 10.37126/aige.v2.i4.127] [Reference Citation Analysis]
291 Ito T, Ishigami M, Morooka H, Yamamoto K, Imai N, Ishizu Y, Honda T, Nishimura D, Tada T, Yasuda S, Toyoda H, Kumada T, Fujishiro M. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep 2020;10:17812. [PMID: 33082429 DOI: 10.1038/s41598-020-74732-3] [Reference Citation Analysis]
292 Zhang YL, Nie CH, Chen F, Zhou TY, Zhou GH, Zhu TY, Chen SQ, Chen XH, Wang HL, Wang BQ, Yu ZN, Jing L, He ZM, Sun JH. Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2020;10:1754. [PMID: 32984060 DOI: 10.3389/fonc.2020.01754] [Reference Citation Analysis]
293 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Clinical Liver Disease 2019;13:1-1. [DOI: 10.1002/cld.802] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
294 Ueno A, Masugi Y, Yamazaki K, Kurebayashi Y, Tsujikawa H, Effendi K, Ojima H, Sakamoto M. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 2020;70:140-54. [PMID: 31908112 DOI: 10.1111/pin.12895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
295 Mähringer‐kunz A, Wagner F, Hahn F, Weinmann A, Brodehl S, Schotten S, Hinrichs JB, Düber C, Galle PR, Pinto dos Santos D, Kloeckner R. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. Liver Int 2019;40:694-703. [DOI: 10.1111/liv.14380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
296 Tsilimigras DI, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. Ann Surg Oncol 2020;27:866-74. [DOI: 10.1245/s10434-019-08025-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
297 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
298 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
299 Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers (Basel) 2020;12:E3048. [PMID: 33092011 DOI: 10.3390/cancers12103048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
300 Haeffele C, Aggarwal A, Lutchman G, Veldtman GR, Wu FM, Lui GK. Fontan Liver Lesions: Not Always HCC. JACC Case Rep 2019;1:175-8. [PMID: 34316779 DOI: 10.1016/j.jaccas.2019.05.031] [Reference Citation Analysis]
301 Chen J, Mitra A, Li S, Song S, Nguyen BN, Chen JS, Shin JH, Gough NR, Lin P, Obias V, He AR, Yao Z, Malta TM, Noushmehr H, Latham PS, Su X, Rashid A, Mishra B, Wu RC, Mishra L. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. Cancer Res 2020;80:1819-32. [PMID: 32127355 DOI: 10.1158/0008-5472.CAN-19-3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
302 Geyer T, Rübenthaler J, Marschner C, von Hake M, Fabritius MP, Froelich MF, Huber T, Nörenberg D, Rückel J, Weniger M, Martens C, Sabel L, Clevert DA, Schwarze V. Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. Cancers (Basel) 2021;13:534. [PMID: 33572502 DOI: 10.3390/cancers13030534] [Reference Citation Analysis]
303 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
304 Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, Ganger D, Maddur H, Moore C, Hohlastos E, Katariya N, Caicedo JC, Kalyan A, Lewandowski RJ, Salem R. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72:1151-1158. [PMID: 32145255 DOI: 10.1016/j.jhep.2020.02.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
305 Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32239989 DOI: 10.1200/EDBK_280625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Zhou K, Pickering TA, Gainey CS, Cockburn M, Stern MC, Liu L, Unger JB, El-Khoueiry AB, Terrault NA. Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma. JNCI Cancer Spectr 2021;5:pkaa100. [PMID: 33442663 DOI: 10.1093/jncics/pkaa100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
308 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
309 Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Higaki S, Fujii I, Suzuki C, Shindo Y, Tokumitsu Y, Nagano H, Sakaida I, Yamasaki T. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun 2020;4:461-70. [PMID: 32140662 DOI: 10.1002/hep4.1469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
310 John BV, Aubuchon S, Dahman B, Konjeti VR, Heuman D, Hubert J, Thomas S, Deng Y, Solomon C, Sundaram LT, Love E, Singal AG, Tatum JL. Addition of [18 F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma. Liver Transpl 2020;26:774-84. [PMID: 32128966 DOI: 10.1002/lt.25743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
311 Tampaki M, Papatheodoridis GV, Cholongitas E. Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clin J Gastroenterol 2021;14:699-713. [PMID: 33774785 DOI: 10.1007/s12328-021-01394-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
312 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
313 Lee IJ, Lee JH, Lee YB, Kim YJ, Yoon JH, Yin YH, Lee M, Hur S, Kim HC, Jae HJ, Chung JW. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Ther Adv Med Oncol 2019;11:1758835919866072. [PMID: 31447948 DOI: 10.1177/1758835919866072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
314 Farha M, Jairath NK, Lawrence TS, El Naqa I. Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.JCO Clin Cancer Inform. 2020;4:1002-1013. [PMID: 33136432 DOI: 10.1200/CCI.20.00077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
316 Weng S, Xu X, Li Y, Yan C, Chen J, Ye R, Zhu Y, Wen L, Hong J. Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma. Ann Transl Med 2020;8:1023. [PMID: 32953823 DOI: 10.21037/atm-20-2874] [Reference Citation Analysis]
317 Xiong MJ, Patel CR, Manne U, Al Diffalha S. Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature. Hepat Oncol 2020;8:HEP28. [PMID: 33680429 DOI: 10.2217/hep-2020-0015] [Reference Citation Analysis]
318 Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, Lee HC, Jung J, Park JH, Kim JH, Kim SY, Yoon SM. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol 2021;36:1962-70. [PMID: 33594690 DOI: 10.1111/jgh.15442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Sun T, Zhang J. ETV4 mediates the wnt/β-catenin pathway through transcriptional activation of ANXA2 to promote hepatitis B virus-associated liver hepatocellular carcinoma progression. J Biochem 2021:mvab088. [PMID: 34347084 DOI: 10.1093/jb/mvab088] [Reference Citation Analysis]
320 Sanders K, Thomas A, Isache C, Siddiqi A. A Rare Case of Metastatic Hepatocellular Carcinoma Masquerading as a Forehead Hematoma. Case Rep Gastrointest Med 2020;2020:8842936. [PMID: 33062352 DOI: 10.1155/2020/8842936] [Reference Citation Analysis]
321 Reimer RP, Große Hokamp N, Fehrmann Efferoth A, Krauskopf A, Zopfs D, Kröger JR, Persigehl T, Maintz D, Bunck AC. Virtual monoenergetic images from spectral detector computed tomography facilitate washout assessment in arterially hyper-enhancing liver lesions. Eur Radiol 2021;31:3468-77. [PMID: 33180163 DOI: 10.1007/s00330-020-07379-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
322 Kardashian A, Patel AA, Aby ES, Cusumano VT, Soroudi C, Winters AC, Wu E, Beah P, Delshad S, Kim N, Yang L, May FP. Identifying Quality Gaps in Preventive Care for Outpatients With Cirrhosis Within a Large, Academic Health Care System. Hepatol Commun 2020;4:1802-11. [PMID: 33305151 DOI: 10.1002/hep4.1594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
323 Han LY, Yang JR, Zhao ZH, Gao S, Fan YC, Wang K. RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2020;216:153147. [PMID: 32853963 DOI: 10.1016/j.prp.2020.153147] [Reference Citation Analysis]
324 Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 2020;72:990-1002. [PMID: 32044402 DOI: 10.1016/j.jhep.2020.01.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 31.0] [Reference Citation Analysis]
325 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
326 Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clin Exp Med 2021. [PMID: 34275027 DOI: 10.1007/s10238-021-00742-8] [Reference Citation Analysis]
327 Leeming DJ, Nielsen SH, Vongsuvanh R, Uchila P, Nielsen MJ, Reese-Petersen AL, van der Poorten D, Eslam M, Schuppan D, Karsdal MA, George J. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepat Oncol 2020;8:HEP32. [PMID: 34084451 DOI: 10.2217/hep-2020-0030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Guo C, Baluya DL, Thompson EA, Whitley EM, Cressman ENK. Correlation of molecular and morphologic effects of thermoembolization in a swine model using mass spectrometry imaging. J Mass Spectrom 2020;55:e4477. [PMID: 31804009 DOI: 10.1002/jms.4477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
330 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]
331 Kedia SK, Ali B, Jiang Y, Arshad H, Satapathy SK, Gonzalez HC. Post-liver transplant outcomes in patients with major psychiatric diagnosis in the United States. Ann Hepatol 2021;22:100311. [PMID: 33482365 DOI: 10.1016/j.aohep.2021.100311] [Reference Citation Analysis]
332 Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392 [PMID: 33815680 DOI: 10.4254/wjh.v13.i3.384] [Reference Citation Analysis]
333 Cabrera R, Singal AG, Colombo M, Kelley RK, Lee H, Mospan AR, Meyer T, Newell P, Parikh ND, Sangro B, Reddy KR, Watkins S, Zink RC, Di Bisceglie AM. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. Hepatol Commun 2021;5:538-47. [PMID: 33681685 DOI: 10.1002/hep4.1652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Kalifu B, Meng Y, Maimaitinijiati Y, Ma ZG, Tian GL, Wang JG, Chen X. Radical resection of hepatic polycystic echinococcosis complicated with hepatocellular carcinoma: A case report. World J Clin Cases 2021; 9(3): 659-665 [PMID: 33553405 DOI: 10.12998/wjcc.v9.i3.659] [Reference Citation Analysis]
335 Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2021:S0016-5085(21)03652-0. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Reference Citation Analysis]
336 Kang H, Lee JM, Yoon JH, Lee K, Kim H, Han JK. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk. Radiology 2020;297:108-16. [DOI: 10.1148/radiol.2020200115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
337 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:2694-701. [PMID: 33854629 DOI: 10.7150/jca.56436] [Reference Citation Analysis]
339 German MN, Lutz MK, Pickhardt PJ, Bruce RJ, Said A. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study. Journal of Clinical Gastroenterology 2020;54:733-40. [DOI: 10.1097/mcg.0000000000001260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
340 Chen Y, Lee J, Sridhar S(, Mittal V, Mccallister K, Singal AG. Improving Cancer Outreach Effectiveness Through Targeting and Economic Assessments: Insights from a Randomized Field Experiment. Journal of Marketing 2020;84:1-27. [DOI: 10.1177/0022242920913025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 12.0] [Reference Citation Analysis]
341 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
342 Sumiya T, Mizumoto M, Oshiro Y, Baba K, Murakami M, Shimizu S, Nakamura M, Hiroshima Y, Ishida T, Iizumi T, Saito T, Numajiri H, Nakai K, Okumura T, Sakurai H. Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1840. [PMID: 32650519 DOI: 10.3390/cancers12071840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
344 Aby ES, Winters AC, Lin J, Bui A, Kawamoto J, Goetz MB, Bhattacharya D, Pisegna JR, May FP, Patel AA, Benhammou JN. A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. Hepatol Commun 2020;4:825-33. [PMID: 32490319 DOI: 10.1002/hep4.1511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:790. [PMID: 33672827 DOI: 10.3390/cancers13040790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
346 Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
347 Wang JC, Fu R, Tao XW, Mao YF, Wang F, Zhang ZC, Yu WW, Chen J, He J, Sun BC. A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data.Biomark Res. 2020;8:47. [PMID: 32963787 DOI: 10.1186/s40364-020-00219-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
348 Tan Z, Lu J, Zhu G, Chen L, Wang Y, Zhang Q, Pan T, Wang J, Guo J, Teng G. Portal Vein Irradiation Stent Plus Chemoembolization versus External Radiotherapy Plus Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Retrospective Study. Cardiovasc Intervent Radiol 2021;44:1414-22. [PMID: 34131776 DOI: 10.1007/s00270-021-02889-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Kang JH, Choi SH, Kim SY, Lee SJ, Shin YM, Won HJ, Kim PN. US LI-RADS visualization score: diagnostic outcome of ultrasound-guided focal hepatic lesion biopsy in patients at risk for hepatocellular carcinoma. Ultrasonography 2021;40:167-75. [PMID: 32623854 DOI: 10.14366/usg.19066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
350 Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, Lee SS, Shin YM, Won HJ, Kim P. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut 2019;68:1719-21. [DOI: 10.1136/gutjnl-2019-318555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
351 Gan X, Luo Y, Dai G, Lin J, Liu X, Zhang X, Li A. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage. Front Genet 2020;11:857. [PMID: 32849835 DOI: 10.3389/fgene.2020.00857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
352 Zou H, Tuhin IJ, Monty MA, Luo S, Shao J, Yan Z, Yu L. Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments. Hum Gene Ther 2020;31:1074-85. [PMID: 32390483 DOI: 10.1089/hum.2019.169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Lim J, Kim KW, Ko Y, Jang IY, Lee YS, Chung YH, Lee HC, Lim YS, Kim KM, Shim JH, Choi J, Lee D. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer 2021;21:1164. [PMID: 34715813 DOI: 10.1186/s12885-021-08905-2] [Reference Citation Analysis]
354 Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
355 Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2019;17:1228-38. [DOI: 10.1016/j.cgh.2018.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
356 Wang C, Liao Y, Qiu J, Yuan Y, Zhang Y, Li K, Zou R, Wang Y, Zuo D, He W, Zheng Y, Li B, Yuan Y. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2020;146:2669-80. [PMID: 32449005 DOI: 10.1007/s00432-020-03254-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
357 Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, Inoue D, Ogi T, Yoshida K, Gabata T. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background. Eur Radiol 2020;30:3438-47. [PMID: 32064560 DOI: 10.1007/s00330-020-06687-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
358 Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019;157:1253-1263.e2. [PMID: 31374215 DOI: 10.1053/j.gastro.2019.07.040] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 26.5] [Reference Citation Analysis]
359 Collettini F, Reimann C, Brangsch J, Chapiro J, Savic LJ, Onthank DC, Robinson SP, Karst U, Buchholz R, Keller S, Hamm B, Goldberg SN, Makowski MR. Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. Sci Rep 2021;11:6814. [PMID: 33767303 DOI: 10.1038/s41598-021-86417-6] [Reference Citation Analysis]
360 Carr J, Cha DE, Shaltiel T, Zheng S, Siderides C, Golas B, Labow D, Magge D, Cohen N, Branch A, Sarpel U. African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality. J Immigr Minor Health 2021. [PMID: 33907933 DOI: 10.1007/s10903-021-01205-8] [Reference Citation Analysis]
361 Huang Y, Huang X, Zeng J, Lin J. Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. Front Oncol 2021;11:667669. [PMID: 34150633 DOI: 10.3389/fonc.2021.667669] [Reference Citation Analysis]
362 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
363 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
364 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Lokken RP, Kerlan RK , Jr, Chung YC, Chen YF, Mehta NJ, Yao FY, Fidelman N. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol 2021;216:1283-90. [PMID: 33703926 DOI: 10.2214/AJR.20.23478] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Tak KY, Jang B, Lee SK, Nam HC, Sung PS, Bae SH, Choi JY, Yoon SK, Jang JW. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol 2021. [PMID: 34031909 DOI: 10.1111/jgh.15553] [Reference Citation Analysis]
367 Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2021. [PMID: 34695288 DOI: 10.1111/jvh.13627] [Reference Citation Analysis]
368 Zhao Z, Song J, Zhang D, Wu F, Tu J, Ji J. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci 2021;264:118642. [PMID: 33148422 DOI: 10.1016/j.lfs.2020.118642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
369 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
370 Cannella R, Cunha GM, Catania R, Chupetlovska K, Borhani AA, Fowler KJ, Furlan A. Magnetic Resonance Imaging of Nonhepatocellular Malignancies in Chronic Liver Disease. Magn Reson Imaging Clin N Am 2021;29:404-18. [PMID: 34243926 DOI: 10.1016/j.mric.2021.05.009] [Reference Citation Analysis]
371 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
372 Feng Z, Zhao H, Jiang Y, He Z, Sun X, Rong P, Wang W. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis. Clinical Nutrition 2020;39:3132-9. [DOI: 10.1016/j.clnu.2020.01.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
373 Tomita K, Shimazu M, Takano K, Gunji T, Ozawa Y, Sano T, Chiba N, Abe Y, Kawachi S. Resection of recurrent hepatocellular carcinoma with thrombi in the inferior vena cava, right atrium, and phrenic vein: a report of three cases. World J Surg Oncol 2020;18:138. [PMID: 32571339 DOI: 10.1186/s12957-020-01914-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Muñoz AE, Pollarsky FD, Marino M, Cartier M, Vázquez H, Salgado P, Romero G. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy. World J Gastroenterol 2021; 27(28): 4639-4652 [PMID: 34366626 DOI: 10.3748/wjg.v27.i28.4639] [Reference Citation Analysis]
375 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
376 Kang H, Kim JH, Joo I, Han JK. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4. Abdom Radiol 2020;45:55-63. [DOI: 10.1007/s00261-019-02132-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
377 Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Reference Citation Analysis]
378 Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH;  REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587-598. [PMID: 31463665 DOI: 10.1007/s12072-019-09974-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
379 Ponnoprat D, Inkeaw P, Chaijaruwanich J, Traisathit P, Sripan P, Inmutto N, Na Chiangmai W, Pongnikorn D, Chitapanarux I. Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans.Med Biol Eng Comput. 2020;58:2497-2515. [PMID: 32794015 DOI: 10.1007/s11517-020-02229-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
380 Lee S, Kim SS, Roh YH, Choi JY, Park MS, Kim MJ. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Int 2020;40:1488-97. [PMID: 32145134 DOI: 10.1111/liv.14424] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
381 Lee SH, Yim SY, Shim J, Lee J. Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 109-23. [DOI: 10.1007/978-3-030-21540-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
382 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
383 Ogasawara N, Saitoh S, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy. Hepatol Res 2019;49:1441-50. [DOI: 10.1111/hepr.13418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
384 Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A, Castaing D, Rosmorduc O, Samuel D, Adam R, Cherqui D. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg 2020;272:820-6. [PMID: 32833755 DOI: 10.1097/SLA.0000000000004259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Shiffman ML, Sussman NL, Ravendhran N, Ditmyer M, Kowdley KV, Kugelmas M. Financial Compensation For Hepatologists in Different Practice Settings: Hepatology. Hepatology 2019;69:2664-71. [DOI: 10.1002/hep.30488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 O'Leary C, Mahler M, Soulen MC. Curative-Intent Therapies in Localized Hepatocellular Carcinoma. Curr Treat Options Oncol 2020;21:31. [PMID: 32193784 DOI: 10.1007/s11864-020-0725-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
387 Jiang X, Tan HY, Teng S, Chan YT, Wang D, Wang N. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E647. [PMID: 31083406 DOI: 10.3390/cancers11050647] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
388 Yang Y, Yu H, Tan X, You Y, Liu F, Zhao T, Qi J, Li J, Feng Y, Zhu Q. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2021;38:875-86. [PMID: 34078221 DOI: 10.1080/02656736.2021.1933218] [Reference Citation Analysis]
389 Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Loomba R, Izumi N. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clin Infect Dis 2021:ciaa1307. [PMID: 33544129 DOI: 10.1093/cid/ciaa1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
390 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
391 Liang L, Wang MD, Zhang YM, Zhang WG, Zhang CW, Lau WY, Shen F, Pawlik TM, Huang DS, Yang T. Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). J Hepatocell Carcinoma 2021;8:103-18. [PMID: 33748017 DOI: 10.2147/JHC.S289840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Tsai HM, Han MZ, Lin YJ, Chang TT, Chen CY, Cheng PN, Chuang CH, Wu IC, Chen PJ, Kang JW, Chiu YC, Chiu HC, Chien SC, Kuo HY. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunol Immunother 2021;70:1929-37. [PMID: 33409737 DOI: 10.1007/s00262-020-02845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
393 Vyas M, Zhang X. Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:591-610. [DOI: 10.1016/j.cld.2020.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
394 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol 2021;44:1048-59. [PMID: 33709273 DOI: 10.1007/s00270-021-02805-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Gessain G, Blériot C, Ginhoux F. Non-genetic Heterogeneity of Macrophages in Diseases-A Medical Perspective. Front Cell Dev Biol 2020;8:613116. [PMID: 33381508 DOI: 10.3389/fcell.2020.613116] [Reference Citation Analysis]
396 Zhang F, Lu C, Zhang X, Chen Z, Zhong C, Hu Y, Wei X, Zhou B, Wang K, Chai Z, Wu M, Lau WY, Cheng S. The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. HPB 2020;22:1025-33. [DOI: 10.1016/j.hpb.2019.10.2439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
397 Morishita J, Inoue T. Determining desire to live among patients with advanced hepatobiliary-pancreatic cancer for whom curative treatment is not indicated. Glob Health Med 2021;3:163-70. [PMID: 34250292 DOI: 10.35772/ghm.2021.01017] [Reference Citation Analysis]
398 Wang SH, Yeh SH, Chen PJ. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers (Basel) 2021;13:2454. [PMID: 34070067 DOI: 10.3390/cancers13102454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
399 Qin M, Wang D, Fang Y, Zheng Z, Liu X, Wu F, Wang L, Li X, Hui B, Ma S, Tang W, Pan X. Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. Front Oncol 2021;11:647854. [PMID: 34235074 DOI: 10.3389/fonc.2021.647854] [Reference Citation Analysis]
400 Moura Cunha G, Chernyak V, Fowler KJ, Sirlin CB. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:513-27. [PMID: 34104640 DOI: 10.2147/JHC.S268288] [Reference Citation Analysis]
401 Ichikawa S, Isoda H, Shimizu T, Tamada D, Taura K, Togashi K, Onishi H, Motosugi U. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study. Eur Radiol 2020;30:5992-6002. [PMID: 32500195 DOI: 10.1007/s00330-020-06972-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 Zhang XP, Zhou TF, Feng JK, Sun ZY, Zhen ZJ, Zhou D, Zhang F, Hu YR, Zhong CQ, Chen ZH, Chai ZT, Wang K, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Association of Preoperative Coagulability With Incidence and Extent of Portal Vein Tumor Thrombus and Survival Outcomes in Hepatocellular Carcinoma After Hepatectomy: A Large-Scale, Multicenter Study. Front Oncol 2021;11:697073. [PMID: 34395264 DOI: 10.3389/fonc.2021.697073] [Reference Citation Analysis]
403 Jeong J, Shin JW, Jung SW, Lee SB, Park EJ, Park NH. Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy. Hepatol Res 2021;51:923-32. [PMID: 34224182 DOI: 10.1111/hepr.13690] [Reference Citation Analysis]
404 Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, Pryor DI. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol 2021;36:873-84. [PMID: 32632941 DOI: 10.1111/jgh.15175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
405 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
406 Zhuang BW, Xie XH, Yang DP, Lin MX, Wang W, Lu MD, Kuang M, Xie XY. Percutaneous thermal ablation of hepatic tumors: local control efficacy and risk factors for artificial ascites failure. Int J Hyperthermia 2021;38:461-70. [PMID: 33752538 DOI: 10.1080/02656736.2021.1882708] [Reference Citation Analysis]
407 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Kielar AZ, Elsayes KM, Chernyak V, Tang A, Sirlin CB. LI-RADS version 2018: What is new and what does this mean to my radiology reports? Abdom Radiol 2019;44:41-2. [DOI: 10.1007/s00261-018-1730-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
410 Lyu N, Kong Y, Pan T, Mu L, Sun X, Li S, Deng H, Lai J, Zhao M. Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma. International Journal of Hyperthermia 2019;36:1002-10. [DOI: 10.1080/02656736.2019.1663279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
411 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
412 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
413 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
414 Lee S, Kim M, Kim S, Shin H, Kim DY, Choi J, Park M, Mitchell DG. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 2020;14:70-9. [DOI: 10.1007/s12072-019-10002-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
415 Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, Fu S, Jiang B, Liu H, Pan Z, Lau WY, Zhou W. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Cancer Med 2021;10:2100-11. [PMID: 33650288 DOI: 10.1002/cam4.3814] [Reference Citation Analysis]
416 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
417 Chen J, Gingold JA, Su X. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends Mol Med 2019;25:1010-23. [PMID: 31353124 DOI: 10.1016/j.molmed.2019.06.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 21.5] [Reference Citation Analysis]
418 Kang HJ, Lee JM, Jeon SK, Jang S, Park S, Joo I, Yoon JH, Han JK. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI. Eur Radiol 2021;31:824-33. [PMID: 32845387 DOI: 10.1007/s00330-020-07162-4] [Reference Citation Analysis]
419 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
420 Alqahtani SA, Schattenberg JM. NAFLD in the Elderly. Clin Interv Aging 2021;16:1633-49. [PMID: 34548787 DOI: 10.2147/CIA.S295524] [Reference Citation Analysis]
421 Ren A, Zhao P, Yang D, Du J, Wang Z, Yang Z. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017: LI-RADS v2018 of MRI for Diagnosing HCC. J Magn Reson Imaging 2019;50:746-55. [DOI: 10.1002/jmri.26640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
422 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
423 Sagawa T, Kogiso T, Sugiyama H, Hashimoto E, Yamamoto M, Tokushige K. Characteristics of hepatocellular carcinoma arising from Fontan‐associated liver disease. Hepatol Res 2020;50:853-62. [DOI: 10.1111/hepr.13500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
424 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Santillan C, Sirlin CB, Mitchell DG, Cerny M, Tang A, Elsayes KM, Kamaya A, Kono Y, Arora SS. An update for LI‐RADS: Version 2018. Why so soon after version 2017? J Magn Reson Imaging 2019;50:1990-1. [DOI: 10.1002/jmri.26715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
425 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
427 Hernandez-Meza G, Violi NV, Said D, Novogrodsky E, Villavisanis D, Maron SZ, Frere J, Schiano TD, Friedman S, Boffetta P, Branch A, Taouli B. MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdom Radiol (NY) 2021. [PMID: 34283266 DOI: 10.1007/s00261-021-03212-7] [Reference Citation Analysis]
428 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
429 Fateen W, Johnson PJ, Wood HM, Zhang H, He S, El-Meteini M, Wyatt JI, Aithal GP, Quirke P. Characterisation of dysplastic liver nodules using low-pass DNA sequencing and detection of chromosome arm-level abnormalities in blood-derived cell-free DNA. J Pathol 2021;255:30-40. [PMID: 34028025 DOI: 10.1002/path.5734] [Reference Citation Analysis]
430 Ratana-Amornpin S, Vilaichone RK, Miftahussurur M, Aumpan N, Kaewkarnjanarat K, Nun-Anan P, Chonprasertsuk S, Siramolpiwat S, Bhanthumkomol P, Pornthisarn B, Uchida T, Mahachai V. Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations. Int J Womens Health 2021;13:717-25. [PMID: 34326670 DOI: 10.2147/IJWH.S311419] [Reference Citation Analysis]
431 Kono Y, Sirlin CB, Fetzer DT, Kim TK, Rodgers SK, Piscaglia F, Lyshchik A, Dietrich CF, Wilson SR. Time to Clarify Common Misconceptions about the Liver Imaging Reporting and Data System for Contrast-enhanced US. Radiology 2020;295:245-7. [DOI: 10.1148/radiol.2020192557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
432 Schoenberger H, Chong N, Fetzer DT, Rich NE, Yokoo T, Khatri G, Olivares J, Parikh ND, Yopp AC, Marrero JA, Singal AG. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00615-7. [PMID: 34119640 DOI: 10.1016/j.cgh.2021.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
433 Motz VL, White R, Lee R, Vu T, Shin B, McGillen KL. Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. Abdom Radiol (NY) 2021;46:4170-7. [PMID: 33956204 DOI: 10.1007/s00261-021-03104-w] [Reference Citation Analysis]
434 Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One 2021;16:e0244939. [PMID: 33439893 DOI: 10.1371/journal.pone.0244939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, Xu L, Wang K, Chai ZT, Guo WX, Shi J, Xie D, Wu MC, Yee Lau W, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology. 2019;69:2076-2090. [PMID: 30586158 DOI: 10.1002/hep.30490] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
436 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangui P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020;12:E452. [PMID: 32075133 DOI: 10.3390/cancers12020452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
437 Wang W, Yang C, Zhu K, Yang L, Ding Y, Luo R, Zhu S, Chen C, Sun W, Zeng M, Rao SX. Recurrence After Curative Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. Liver Transpl 2020;26:751-63. [PMID: 31901208 DOI: 10.1002/lt.25713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
438 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
439 Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, Hou ZH, Huang P, Zhang S, Li Z, Zhu XL, Ni CF. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. AJR Am J Roentgenol 2021;217:933-43. [PMID: 33245680 DOI: 10.2214/AJR.20.24708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
440 Chen S, Zhang J, Chen Q, Cheng J, Chen X, Mao Y, Chen W, Liu C, Wu H, Lv Y, Lin Y. MicroRNA-200a and microRNA-141 have a synergetic effect on the suppression of epithelial-mesenchymal transition in liver cancer by targeting STAT4. Oncol Lett 2021;21:137. [PMID: 33552256 DOI: 10.3892/ol.2020.12398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
441 Wang H, Jin C, Fang L, Sun H, Cheng W, Hu S. Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review. Cost Eff Resour Alloc 2020;18:1. [PMID: 31938024 DOI: 10.1186/s12962-019-0198-z] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
442 Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu Y, Zhang S, Phillips JL, Hernaez R. Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:987-995.e1. [PMID: 32629122 DOI: 10.1016/j.cgh.2020.06.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
443 Sinharay R, Grant AJ, Rivett L, Blackwell R, Mells G, Gelson W. Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era. GastroHep 2021;3:80-7. [PMID: 33821150 DOI: 10.1002/ygh2.443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
444 Tsilimigras DI, Bagante F, Moris D, Merath K, Paredes AZ, Sahara K, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery 2019;166:967-74. [DOI: 10.1016/j.surg.2019.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
445 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
446 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 212] [Cited by in F6Publishing: 196] [Article Influence: 70.7] [Reference Citation Analysis]
447 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
448 Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147:317-330. [PMID: 31597196 DOI: 10.1002/ijc.32723] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
449 Lu F, Shah PA, Rao A, Gifford-Hollingsworth C, Chen A, Trey G, Soryal M, Talat A, Aslam A, Nasir B, Choudhry S, Ishtiaq R, Sanoff H, Conteh LF, Noonan A, Hu KQ, Schmidt C, Fu M, Civan J, Xiao G, Lau DT, Lu X. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00271. [PMID: 33512798 DOI: 10.14309/ctg.0000000000000271] [Reference Citation Analysis]
450 Mejia JC, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Clin North Am 2020;100:535-49. [PMID: 32402299 DOI: 10.1016/j.suc.2020.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
451 Sun HC, Zhu XD, Zhou J, Gao Q, Shi YH, Ding ZB, Huang C, Qiu SJ, Ren N, Shi GM, Sun J, Ye QH, Huang XW, Yang XR, Fan J. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Ann Transl Med 2020;8:1301. [PMID: 33209881 DOI: 10.21037/atm-20-6181] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
453 Pinyopornpanish K, Al-Yaman W, Butler RS, Carey W, McCullough A, Romero-Marrero C. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021. [PMID: 34212895 DOI: 10.14309/ajg.0000000000001347] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Liu H, Chen Q, Lu D, Pang X, Yin S, Wang K, Wang R, Yang S, Zhang Y, Qiu Y, Wang T, Yu H. HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt. FASEB j 2020;34:12255-68. [DOI: 10.1096/fj.202000254r] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
455 Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Hum Pathol 2021;113:39-46. [PMID: 33905775 DOI: 10.1016/j.humpath.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
456 Xu C, Zheng H, Shi T, Qi J, Zhao X, Li J, Feng Y, Zhu Q. A prediction model of major complications after radiofrequency ablation for recurrent hepatocellular carcinoma patients. Eur J Radiol 2021;140:109635. [PMID: 34024632 DOI: 10.1016/j.ejrad.2021.109635] [Reference Citation Analysis]
457 Le PH, Kuo CJ, Hsieh YC, Chen TH, Lin CL, Yeh CT, Liang KH. Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation. BMC Cancer 2019;19:1190. [PMID: 31805979 DOI: 10.1186/s12885-019-6409-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
459 Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, Park JS, Dagher NN, Taslakian B, Hickey RM. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:25-34. [PMID: 31422022 DOI: 10.1016/j.jvir.2019.05.023] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
460 Liu XY, Wang JQ, Ashby CR Jr, Zeng L, Fan YF, Chen ZS. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today 2021;26:1284-92. [PMID: 33549529 DOI: 10.1016/j.drudis.2021.01.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
461 Yoon JH, Goo YJ, Lim CJ, Choi SK, Cho SB, Shin SS, Jun CH. Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2020; 26(32): 4833-4845 [PMID: 32921960 DOI: 10.3748/wjg.v26.i32.4833] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
462 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology 2019;292:638-46. [PMID: 31287387 DOI: 10.1148/radiol.2019190183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
463 Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
464 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Reference Citation Analysis]
465 Fung A, Shanbhogue KP, Taffel MT, Brinkerhoff BT, Theise ND. Hepatocarcinogenesis: Radiology-Pathology Correlation. Magn Reson Imaging Clin N Am 2021;29:359-74. [PMID: 34243923 DOI: 10.1016/j.mric.2021.05.007] [Reference Citation Analysis]
466 Kang JH, Choi SH, Byun JH, Kim DH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim P. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging. Eur Radiol 2020;30:2881-9. [DOI: 10.1007/s00330-019-06645-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
467 Morisaka H, Motosugi U, Ichikawa S, Ichikawa T, Kondo T, Onishi H. Uptake of gadoxetic acid in hepatobiliary phase magnetic resonance imaging and transporter expression in hypovascular hepatocellular nodules. Eur J Radiol 2021;138:109669. [PMID: 33770738 DOI: 10.1016/j.ejrad.2021.109669] [Reference Citation Analysis]
468 Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021. [PMID: 33728665 DOI: 10.1002/hep.31811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
469 Lee S, Kim KW, Jeong WK, Kim M, Choi GH, Choi JS, Song G, Lee S. Gadoxetic acid–enhanced MRI as a predictor of recurrence of HCC after liver transplantation. Eur Radiol 2020;30:987-95. [DOI: 10.1007/s00330-019-06424-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
470 Chen ZH, Zhang XP, Wang K, Sun JX, Chai ZT, Yang Y, Guo WX, Shi J, Lau WY, Cheng SQ. Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: A propensity score matching analysis. Hepatol Res 2019;49:441-52. [PMID: 30549370 DOI: 10.1111/hepr.13297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
471 Wang XJ, Li FF, Zhang YJ, Jiang M, Ren WH. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis. Cancer Biomark 2020;29:307-15. [PMID: 32716348 DOI: 10.3233/CBM-201577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
472 Wang D, Xu Y, Goldstein JB, Ye K, Hu X, Xiao L, Li L, Chang L, Guan Y, Long G, He Q, Yi X, Zhang J, Wang Z, Xia X, Zhou L. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int 2020;40:1997-2007. [PMID: 32279416 DOI: 10.1111/liv.14463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
473 Xu X, Zhang HL, Liu QP, Sun SW, Zhang J, Zhu FP, Yang G, Yan X, Zhang YD, Liu XS. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70:1133-1144. [PMID: 30876945 DOI: 10.1016/j.jhep.2019.02.023] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 60.5] [Reference Citation Analysis]
474 Lai Q, Di Martino M, Lucatelli P, Mennini G. Locoregional therapy response in patients with hepatocellular cancer waiting for liver transplantation: Only selection or biological effect? World J Gastroenterol 2018; 24(31): 3469-3471 [PMID: 30131653 DOI: 10.3748/wjg.v24.i31.3469] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
475 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
476 Shin J, Lee S, Yoon JK, Chung YE, Choi J, Park M. LI‐RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. J Magn Reson Imaging 2021;54:518-25. [DOI: 10.1002/jmri.27570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
477 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
478 Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP. Laparoscopic liver resection for huge (≥10 cm) hepatocellular carcinoma: A coarsened exact-matched single-surgeon study. Surg Oncol 2021;37:101569. [PMID: 33839442 DOI: 10.1016/j.suronc.2021.101569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Yoo J, Lee MW, Lee DH, Lee JH, Han JK. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int 2020;40:1189-200. [PMID: 32056353 DOI: 10.1111/liv.14406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
480 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
481 Seo JY, Shin DW, Yu SJ, Jung JH, Han K, Cho IY, Kim SY, Choi KS, Park JH, Park JH, Kawachi I. Disparities in Liver Cancer Surveillance Among People With Disabilities: A National Database Study in Korea. J Clin Gastroenterol 2021;55:439-48. [PMID: 32889960 DOI: 10.1097/MCG.0000000000001405] [Reference Citation Analysis]
482 Zhang BH, Cai YS, Song JL, Lyu T, Yang J, Jiang L, Yang JY. Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB. Hepatology 2021;73:1621-2. [PMID: 32965687 DOI: 10.1002/hep.31563] [Reference Citation Analysis]
483 Hwang YJ, Lee Y, Park H, Lee Y, Lee K, Kim H. Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment. J Pathol Transl Med 2021;55:338-48. [PMID: 34465077 DOI: 10.4132/jptm.2021.07.26] [Reference Citation Analysis]
484 Kim TH, Woo S, Han S, Suh CH, Do RKG, Lee JM. Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis. Acad Radiol 2020:S1076-6332(20)30512-2. [PMID: 32962925 DOI: 10.1016/j.acra.2020.08.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Yoon JS, Lee DH, Cho EJ, Song MK, Choi YH, Kim GB, Lee YB, Lee JH, Yu SJ, Kim H, Kim YJ, Yoon JH, Bae EJ. Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance. Cancers (Basel) 2020;12:E1805. [PMID: 32640555 DOI: 10.3390/cancers12071805] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
486 Lee YT, Wang JJ, Zhu Y, Agopian VG, Tseng HR, Yang JD. Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:409-13. [PMID: 34386205 DOI: 10.1002/cld.1075] [Reference Citation Analysis]
487 von Felden J, Karkmann K, Ittrich H, Gil-Ibanez I, Fründt T, Krause J, Lohse AW, Wege H, Schulze K. Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. Visc Med 2021;37:87-93. [PMID: 33981749 DOI: 10.1159/000507381] [Reference Citation Analysis]
488 Ahn HR, Baek GO, Yoon MG, Son JA, You D, Yoon JH, Cho HJ, Kim SS, Cheong JY, Eun JW. HMBS is the most suitable reference gene for RT-qPCR in human HCC tissues and blood samples. Oncol Lett 2021;22:791. [PMID: 34584568 DOI: 10.3892/ol.2021.13052] [Reference Citation Analysis]
489 Possner M, Gordon-Walker T, Egbe AC, Poterucha JT, Warnes CA, Connolly HM, Ginde S, Clift P, Kogon B, Book WM, Walker N, Wagenaar LJ, Moe T, Oechslin E, Kay WA, Norris M, Dillman JR, Trout AT, Anwar N, Hoskoppal A, Broering DC, Bzeizi K, Veldtman G. Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes. Int J Cardiol 2021;322:142-8. [PMID: 32828959 DOI: 10.1016/j.ijcard.2020.08.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
490 Bae SH, Park HC. Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy. Ann Transl Med 2018;6:S3. [PMID: 30613579 DOI: 10.21037/atm.2018.08.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
491 Cannella R, Vernuccio F, Sagreiya H, Choudhury KR, Iranpour N, Marin D, Furlan A. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol 2020;30:3770-81. [PMID: 32107603 DOI: 10.1007/s00330-020-06698-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
492 Kudo M. A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:530-3. [PMID: 32832511 DOI: 10.21037/hbsn-20-420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
493 Ahn YH, Lee H, Kim DY, Lee HW, Yu SJ, Cho YY, Jang JW, Jang BK, Kim CW, Kim HY, Park H, Cho HJ, Park B, Kim SS, Cheong JY. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver 2021;15:410-9. [PMID: 32893194 DOI: 10.5009/gnl20151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
494 Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46:3540-8. [PMID: 33864107 DOI: 10.1007/s00261-021-03074-z] [Reference Citation Analysis]
495 Weiss J, Winkelmann MT, Gohla G, Kübler J, Clasen S, Nikolaou K, Hoffmann R. MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures. Int J Hyperthermia 2020;37:349-55. [PMID: 32286087 DOI: 10.1080/02656736.2020.1750713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
496 Wu Y, White GM, Cornelius T, Gowdar I, Ansari MH, Supanich MP, Deng J. Deep learning LI-RADS grading system based on contrast enhanced multiphase MRI for differentiation between LR-3 and LR-4/LR-5 liver tumors. Ann Transl Med 2020;8:701. [PMID: 32617321 DOI: 10.21037/atm.2019.12.151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
497 Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
498 Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, Xia Y, Li Y, Chen W, Zhao J, Chai J. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol 2020;14:383-400. [PMID: 32240595 DOI: 10.1080/17474124.2020.1748010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
499 Florea M, Serban T, Tirpe GR, Tirpe A, Lupsor-Platon M. Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography. J Clin Med 2021;10:2575. [PMID: 34200885 DOI: 10.3390/jcm10122575] [Reference Citation Analysis]
500 Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, An J, Jung J, Kim JH, Lee HC. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26:506-15. [PMID: 32646200 DOI: 10.3350/cmh.2020.0038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
501 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
502 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021; 27(22): 2994-3009 [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
503 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
504 Rogal SS, Yakovchenko V, Gonzalez R, Park A, Beste LA, Rozenberg-Ben-Dror K, Bajaj JS, Scott D, McCurdy H, Comstock E, Sidorovic M, Gibson S, Lamorte C, Nobbe A, Chartier M, Ross D, Dominitz JA, Morgan TR. The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance. Cancers (Basel) 2021;13:2251. [PMID: 34067177 DOI: 10.3390/cancers13092251] [Reference Citation Analysis]
505 Zou J, Li C, Chen Y, Chen R, Xue T, Xie X, Zhang L, Ren Z. Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. Oncol Lett 2019;18:6423-30. [PMID: 31807165 DOI: 10.3892/ol.2019.11037] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
506 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
507 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
508 Chen X, Zhang X, Li S, Zhang L, Zhang Q, Chen Z, Li L, Su Z, Cheng S, Wang C. Engineering of Yin Yang-like nanocarriers for varisized guest delivery and synergistic eradication of patient-derived hepatocellular carcinoma. Nanoscale Horiz 2019;4:1046-55. [DOI: 10.1039/c8nh00467f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
509 Zhao W, Jiang L, Fang T, Fang F, Liu Y, Zhao Y, You Y, Zhou H, Su X, Wang J, Liu S, Chen Y, Wan J, Huang X. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation. Front Oncol 2021;11:747282. [PMID: 34676172 DOI: 10.3389/fonc.2021.747282] [Reference Citation Analysis]
510 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
511 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
512 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
513 Lee SM, Lee JM, Ahn SJ, Kang H, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI. Radiology 2019;292:655-63. [DOI: 10.1148/radiol.2019182867] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
514 Bao Y, Suvesh M, Li X, Bai X, Li H, Li X, Xu D, Liu L. Ebp1 p48 promotes oncogenic properties in hepatocellular carcinoma through p38 MAPK/HIF1α activation and p53 downregulation. Mol Carcinog 2021;60:252-64. [PMID: 33634940 DOI: 10.1002/mc.23288] [Reference Citation Analysis]
515 Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
516 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
517 Heimbach JK. United States liver allocation. Current Opinion in Organ Transplantation 2020;25:104-9. [DOI: 10.1097/mot.0000000000000740] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
518 Singal AG, Ioannou GN. For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective? Clin Gastroenterol Hepatol 2019;17:1732-5. [PMID: 30772587 DOI: 10.1016/j.cgh.2019.02.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
519 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, Cheung KS, Yuen MF, Seto WK. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 2021;15:901-11. [PMID: 34152534 DOI: 10.1007/s12072-021-10218-2] [Reference Citation Analysis]
520 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
521 Are VS, Vilar-Gomez E, Gromski MA, Akisik F, Lammert C, Ghabril M, Chalasani N, Vuppalanchi R, Nephew LD. Racial differences in primary sclerosing cholangitis mortality is associated with community socioeconomic status. Liver Int 2021. [PMID: 34240538 DOI: 10.1111/liv.15008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
522 Ko SE, Lee MW, Min JH, Ahn SH, Rhim H, Kang TW, Song KD, Kim JM, Choi GS, Cha DI, Lim HK. Laparoscopic radiofrequency ablation of subcapsular hepatocellular carcinomas: risk factors related to a technical failure. Surg Endosc 2021. [PMID: 33523278 DOI: 10.1007/s00464-021-08310-7] [Reference Citation Analysis]
523 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
524 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
525 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
526 Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C, Nicolay NH, Ihorst G, Bamberg F, Thimme R, Grosu AL, Gkika E. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021;11:653141. [PMID: 33816309 DOI: 10.3389/fonc.2021.653141] [Reference Citation Analysis]
528 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Ahmed O, Pillai A. Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol 2020;115:1733-6. [PMID: 33156085 DOI: 10.14309/ajg.0000000000000931] [Reference Citation Analysis]
530 Alenazi AO, Elsayes KM, Marks RM, Yacoub JH, Hecht EM, Chernyak V, Krishna S, Surabhi V, Lee JT, Ash R, Cruite I, Kielar AZ. Clinicians and surgeon survey regarding current and future versions of CT/MRI LI-RADS. Abdom Radiol 2020;45:2603-11. [DOI: 10.1007/s00261-020-02544-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
531 Eguchi A, Hasegawa H, Iwasa M, Tamai Y, Ohata K, Oikawa T, Sugaya T, Takei Y. Serum Liver-Type Fatty Acid-Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma. Hepatol Commun. 2019;3:825-837. [PMID: 31168516 DOI: 10.1002/hep4.1350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
532 Govalan R, Lauzon M, Luu M, Ahn JC, Kosari K, Todo T, Kim IK, Noureddin M, Kuo A, Walid AS, Sundaram V, Lu SC, Roberts LR, Singal AG, Heimbach JK, Agopian VG, Nissen N, Yang JD. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer 2021;10:407-18. [PMID: 34721504 DOI: 10.1159/000515554] [Reference Citation Analysis]
533 Berman ZT, Newton I. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:441-7. [PMID: 33328699 DOI: 10.1055/s-0040-1719185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
534 Kulkarni CB, Pullara SK, Prabhu NK, Patel S, Suresh A, Moorthy S. Comparison of Knowledge-based Iterative Model Reconstruction (IMR) with Hybrid Iterative Reconstruction (iDose4) Techniques for Evaluation of Hepatocellular Carcinomas Using Computed Tomography. Academic Radiology 2020. [DOI: 10.1016/j.acra.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, Choi SH, Lee SS, An J, Lim YS. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol 2020;72:718-24. [PMID: 31836549 DOI: 10.1016/j.jhep.2019.12.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
536 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
537 Xie Y, Tian H, Xiang B, Zhang Y, Liu J, Cai Z, Xiang H. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes. Medicine (Baltimore) 2021;100:e26958. [PMID: 34414963 DOI: 10.1097/MD.0000000000026958] [Reference Citation Analysis]
538 Cunha GM, Hasenstab KA, Delgado T, Ichikawa S, Lee MH, Dautt Medina PM, Kim SJ, Lee YH, Kwon H, Sirlin CB, Fowler KJ. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33876298 DOI: 10.1007/s00330-021-07924-8] [Reference Citation Analysis]
539 Heller M, Parikh ND, Fidelman N, Owen D. Frontiers of therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3648-59. [PMID: 33837453 DOI: 10.1007/s00261-021-03065-0] [Reference Citation Analysis]
540 Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020;9:F1000 Faculty Rev-620. [PMID: 32595940 DOI: 10.12688/f1000research.24543.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
541 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00080-3. [PMID: 34384724 DOI: 10.1016/j.rgmxen.2021.07.006] [Reference Citation Analysis]
542 Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
543 Tangjarusritaratorn T, Tangjittipokin W, Kunavisarut T. Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin. Diabetes Metab Syndr Obes 2021;14:1563-74. [PMID: 33859487 DOI: 10.2147/DMSO.S295753] [Reference Citation Analysis]
544 Cho CW, Kim JM, Lee BH, Lee DS, Yun SS, Choi GS, Joh JW. Clinical impact of anatomical resection on long-term outcomes after hepatectomy for primary solitary hepatocellular carcinoma with or without preoperative positron emission tomography positivity. Ann Transl Med 2020;8:1377. [PMID: 33313122 DOI: 10.21037/atm-20-1583] [Reference Citation Analysis]
545 Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int. 2020;19:541-546. [PMID: 32660841 DOI: 10.1016/j.hbpd.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
546 Cannella R, Vernuccio F, Celsa C, Cabibbo G, Calvaruso V, Greco S, Battaglia S, Choudhury KR, Tang A, Midiri M, Di Marco V, Cammà C, Brancatelli G. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver Int 2021;41:2179-88. [PMID: 33908147 DOI: 10.1111/liv.14914] [Reference Citation Analysis]
547 Pittman ME. Population-Specific Screening for Hepatocellular Carcinoma. Clin Chem 2019;65:1477-8. [PMID: 31672854 DOI: 10.1373/clinchem.2019.312058] [Reference Citation Analysis]
548 Chai ZT, Zhang XP, Ao JY, Zhu XD, Wu MC, Lau WY, Sun HC, Cheng SQ. AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:650963. [PMID: 34123800 DOI: 10.3389/fonc.2021.650963] [Reference Citation Analysis]
549 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
550 Welberry C, Macdonald I, McElveen J, Parsy-Kowalska C, Allen J, Healey G, Irving W, Murray A, Chapman C. Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma. PLoS One 2020;15:e0232247. [PMID: 32374744 DOI: 10.1371/journal.pone.0232247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
551 Wu CJ, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc 2021;120:1563-71. [PMID: 33334659 DOI: 10.1016/j.jfma.2020.11.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
552 Moris D, Shaw BI, Ong C, Connor A, Samoylova ML, Kesseli SJ, Abraham N, Gloria J, Schmitz R, Fitch ZW, Clary BM, Barbas AS. A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS). Hepatobiliary Surg Nutr 2021;10:315-24. [PMID: 34159159 DOI: 10.21037/hbsn.2020.03.12] [Reference Citation Analysis]
553 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
554 Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology. 2019;157:1264-1278.e4. [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 47.5] [Reference Citation Analysis]
555 Yousaf MN, Ehsan H, Muneeb A, Wahab A, Sana MK, Neupane K, Chaudhary FS. Role of Radiofrequency Ablation in the Management of Unresectable Pancreatic Cancer. Front Med (Lausanne) 2020;7:624997. [PMID: 33644089 DOI: 10.3389/fmed.2020.624997] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, Kimura H, Fujii H, Ishikawa H, Takaharu Y, Ishiba H, Morita A, Jo M, Nagao Y, Arai M, Hara T, Okajima A, Muramatsu A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Okanoue T, Itoh Y. Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. Cancers (Basel) 2020;12:E754. [PMID: 32209994 DOI: 10.3390/cancers12030754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
557 Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T; FibroFrance Group. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Aliment Pharmacol Ther 2018;48:1117-27. [PMID: 30334263 DOI: 10.1111/apt.14990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
558 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
559 Wei JW, Fu SR, Zhang J, Gu DS, Li XQ, Chen XD, Zhang ST, He XF, Yan JF, Lu LG, Tian J. CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma: A multicenter study. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00198-3. [PMID: 34674948 DOI: 10.1016/j.hbpd.2021.09.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
561 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
562 Hectors SJ, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30:3759-3769. [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
563 Cannella R, Calandra A, Cabibbo G, Midiri M, Tang A, Brancatelli G. Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation. European Journal of Radiology 2019;120:108689. [DOI: 10.1016/j.ejrad.2019.108689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
564 Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, Doyle MB. Access to Liver Transplantation for Hepatocellular Carcinoma: Does Candidate Age Matter? J Am Coll Surg 2021;233:140-51. [PMID: 33652155 DOI: 10.1016/j.jamcollsurg.2021.01.018] [Reference Citation Analysis]
565 Park C, Kim JH, Kim PH, Kim SY, Gwon DI, Chu HH, Park M, Hur J, Kim JY, Kim DJ. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol 2021;22:213-24. [PMID: 32901464 DOI: 10.3348/kjr.2020.0325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
566 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
567 Lv JY, Zhang NN, Du YW, Wu Y, Song TQ, Zhang YM, Qu Y, Liu YX, Gu J, Wang ZY, Qiu YB, Yang B, Tian DZ, Guo QJ, Zhang L, Sun JS, Xie Y, Wang ZL, Sun X, Jiang WT, Lu W. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II. Yonsei Med J 2021;62:29-40. [PMID: 33381932 DOI: 10.3349/ymj.2021.62.1.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
568 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
569 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
570 Kim J, Min JH, Kim SK, Shin SY, Lee MW. Detection of Hepatocellular Carcinoma in Contrast-Enhanced Magnetic Resonance Imaging Using Deep Learning Classifier: A Multi-Center Retrospective Study. Sci Rep 2020;10:9458. [PMID: 32527998 DOI: 10.1038/s41598-020-65875-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
571 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Reference Citation Analysis]
572 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
573 Lin YJ, Ho CM. Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. Medicina (Kaunas) 2021;57:131. [PMID: 33540784 DOI: 10.3390/medicina57020131] [Reference Citation Analysis]
574 Lai WW, Chung CH, Lin CN, Yang SC, Hwang JS, Wang JD. QALYs and medical costs saved from prevention of a cancer: Analysis of nation-wide real-world data of Taiwan with lifetime horizon. J Formos Med Assoc 2021:S0929-6646(21)00180-7. [PMID: 34020855 DOI: 10.1016/j.jfma.2021.04.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
575 Liu APY, Soh SY, Cheng FWC, Pang HH, Luk CW, Li CH, Ho KKH, Chan EKW, Chan ACY, Chung PHY, Kimpo MS, Ahamed SH, Loh A, Chiang AKS. Hepatitis B Virus Seropositivity Is a Poor Prognostic Factor of Pediatric Hepatocellular Carcinoma: a Population-Based Study in Hong Kong and Singapore. Front Oncol 2020;10:570479. [PMID: 33330043 DOI: 10.3389/fonc.2020.570479] [Reference Citation Analysis]
576 Agrawal R, Majeed M, Aqeel SB, Wang Y, Haque Z, Omar YA, Upadhyay SB, Gast T, Attar BM, Gandhi S. Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization. Ann Gastroenterol. 2021;34:241-246. [PMID: 33654366 DOI: 10.20524/aog.2020.0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
577 Peta V, Zhu J, Lubman DM, Huguet S, Imbert-Bismutd F, Bolbach G, Clodic G, Matheron L, Ngo Y, Raluca P, Housset C, Rezai K, Poynard T; FibroFrance-Groupe Hospitalier Pitié Salpêtrière (GHPS) Group. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Clin Res Hepatol Gastroenterol 2020;44:681-91. [PMID: 31964615 DOI: 10.1016/j.clinre.2019.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
578 Lucatelli P, De Rubeis G, Ginnani Corradini L, Basilico F, Di Martino M, Lai Q, Ginanni Corradini S, Cannavale A, Nardis PG, Corona M, Saba L, Catalano C, Bezzi M. Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. Eur J Radiol 2020;124:108806. [PMID: 31945673 DOI: 10.1016/j.ejrad.2019.108806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
579 Mospan AR, Morris HL, Fried MW. Real-world evidence in hepatocellular carcinoma. Liver Int 2021;41 Suppl 1:61-7. [PMID: 34155788 DOI: 10.1111/liv.14864] [Reference Citation Analysis]
580 Kim HS, Yi NJ, Kim JM, Joh JW, Lee KW, Suh KS. Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection. Ann Surg Treat Res 2021;101:85-92. [PMID: 34386457 DOI: 10.4174/astr.2021.101.2.85] [Reference Citation Analysis]
581 Chen S, Zhang Z, Wang Y, Fang M, Zhou J, Li Y, Dai E, Feng Z, Wang H, Yang Z, Li Y, Huang X, Jia J, Li S, Huang C, Tong L, Xiao X, He Y, Duan Y, Zhu S, Gao C. Quasispecies pattern of hepatitis B virus predicts hepatocellular carcinoma using deep-sequencing and machine learning. J Infect Dis. 2020;. [PMID: 33049037 DOI: 10.1093/infdis/jiaa647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
582 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
583 Hong SB, Kim DH, Choi SH, Kim SY, Lee JS, Lee NK, Choi JI. Inadequate Ultrasound Examination in Hepatocellular Carcinoma Surveillance: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3535. [PMID: 34441831 DOI: 10.3390/jcm10163535] [Reference Citation Analysis]
584 Tan L, Chen S, Wei G, Li Y, Liao J, Jin H, Zou Y, Huang M, Peng Z, Guo Y, Peng S, Xu L, Kuang M. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Letters 2019;460:29-40. [DOI: 10.1016/j.canlet.2019.05.041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
585 Gomaa SH, Abaza MM, Elattar HA, Amin GA, Elshahawy DM. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab J Gastroenterol 2020;21:224-32. [PMID: 32891543 DOI: 10.1016/j.ajg.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Stolley DL, Crouch AC, Özkan A, Seeley EH, Whitley EM, Rylander MN, Cressman ENK. Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. Pharmaceutics 2020;12:E1243. [PMID: 33419304 DOI: 10.3390/pharmaceutics12121243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
587 Zou X, Luo Y, Morelli JN, Hu X, Shen Y, Hu D. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Abdom Radiol (NY) 2021;46:3168-78. [PMID: 33660040 DOI: 10.1007/s00261-021-02996-y] [Reference Citation Analysis]
588 Kim T, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 2020;30:1624-33. [DOI: 10.1007/s00330-019-06499-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
589 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
590 Ma L, Shao H, Chen H, Deng Q. The Mechanism of miR-141 Regulating the Proliferation and Metastasis of Liver Cancer Cells by Targeting STAT4. J Oncol 2021;2021:5425491. [PMID: 34675977 DOI: 10.1155/2021/5425491] [Reference Citation Analysis]
591 Terzi E, Ayuso C, Piscaglia F, Bruix J. Liver Imaging Reporting and Data System: Review of Pros and Cons. Semin Liver Dis 2021. [PMID: 34298576 DOI: 10.1055/s-0041-1732356] [Reference Citation Analysis]
592 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Reference Citation Analysis]
593 Choi K, Jang HY, Ahn JM, Hwang SH, Chung JW, Choi YS, Kim JW, Jang ES, Choi GH, Jeong SH. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin Mol Hepatol 2020;26:492-505. [PMID: 32646201 DOI: 10.3350/cmh.2020.0005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
594 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 47.0] [Reference Citation Analysis]
595 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
596 Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
597 Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clin Imaging 2021;76:123-9. [PMID: 33592550 DOI: 10.1016/j.clinimag.2021.01.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
598 Marks RM, Ash RM, Lee JT. Gadolinium Deposition and Liver MRI. Clin Liver Dis (Hoboken) 2021;17:129-32. [PMID: 33868652 DOI: 10.1002/cld.1024] [Reference Citation Analysis]
599 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
600 Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020;30:2391-400. [DOI: 10.1007/s00330-019-06575-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
601 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
602 Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol 2020; 12(9): 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
603 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
604 Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases 2021; 9(30): 9059-9069 [DOI: 10.12998/wjcc.v9.i30.9059] [Reference Citation Analysis]
605 Otto G, Pitton MB, Hoppe-Lotichius M, Weinmann A. Liver transplantation and BCLC classification: Limitations impede optimum treatment. Hepatobiliary Pancreat Dis Int 2021;20:6-12. [PMID: 33349607 DOI: 10.1016/j.hbpd.2020.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
606 Kudo M. Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer. 2018;7:215-224. [PMID: 30319981 DOI: 10.1159/000492533] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
607 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
608 Elsayes KM, Fowler KJ, Chernyak V, Elmohr MM, Kielar AZ, Hecht E, Bashir MR, Furlan A, Sirlin CB. User and system pitfalls in liver imaging with LI-RADS. J Magn Reson Imaging 2019;50:1673-86. [PMID: 31215119 DOI: 10.1002/jmri.26839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
609 Kang HJ, Lee JM, Yoon JH, Han JK. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. Korean J Radiol 2021;22:354-65. [PMID: 33236540 DOI: 10.3348/kjr.2020.0973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
610 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
611 Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, Ronald J, Commander L, Hertel J, Luo S, Bashir MR, Burke LMB. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 2020;294:320-326. [PMID: 31845843 DOI: 10.1148/radiol.2019191581] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
612 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
613 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
614 Wang F, Hou W, Chitsike L, Xu Y, Bettler C, Perera A, Bank T, Cotler SJ, Dhanarajan A, Denning MF, Ding X, Breslin P, Qiang W, Li J, Koleske AJ, Qiu W. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Gastroenterology 2020;159:289-305.e16. [PMID: 32171747 DOI: 10.1053/j.gastro.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
615 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
617 Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
618 Subramanian M, Low HM, Kim MJ, Tan CH. Benign focal liver lesions masquerading as primary liver cancers on MRI. Diagn Interv Radiol 2020;26:168-75. [PMID: 32229432 DOI: 10.5152/dir.2019.19235] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
619 Bae JS, Lee DH, Yoo J, Yi NJ, Lee KW, Suh KS, Kim H, Lee KB. Association between spleen volume and the post-hepatectomy liver failure and overall survival of patients with hepatocellular carcinoma after resection. Eur Radiol 2021;31:2461-71. [PMID: 33026503 DOI: 10.1007/s00330-020-07313-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
620 Zhang XP, Wang K, Wei XB, Li LQ, Sun HC, Wen TF, Chai ZT, Chen ZH, Shi J, Guo WX, Xie D, Cong WM, Wu MC, Lau WY, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. Oncologist 2019;24:e1476-88. [PMID: 31138726 DOI: 10.1634/theoncologist.2018-0868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
621 Bae JS, Lee JM, Jeon SK, Yoo J, Park SJ, Yoon JH, Joo I, Lee KB, Kim H. LI-RADS Tumor in Vein at CT and Hepatobiliary MRI. Radiology 2021;:210215. [PMID: 34581625 DOI: 10.1148/radiol.2021210215] [Reference Citation Analysis]
622 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
623 Kim M, Lee S. Should LR‐M and LR‐TIV Remain Separate Categories in LI‐RADS? Hepatology 2019;69:1842-1842. [DOI: 10.1002/hep.30484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
624 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
625 Ivanics T, Patel MS, Erdman L, Sapisochin G. Artificial intelligence in transplantation (machine-learning classifiers and transplant oncology). Curr Opin Organ Transplant 2020;25:426-34. [PMID: 32487887 DOI: 10.1097/MOT.0000000000000773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
626 Franzè MS, Bottari A, Caloggero S, Pitrone A, Barbera A, Lembo T, Caccamo G, Cacciola I, Maimone S, Alibrandi A, Pitrone C, Squadrito G, Raimondo G, Saitta C. Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules. Intern Emerg Med 2021;16:949-55. [PMID: 33111165 DOI: 10.1007/s11739-020-02541-7] [Reference Citation Analysis]
627 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
628 Boldrini L, Romano A, Mariani S, Cusumano D, Catucci F, Placidi L, Mattiucci GC, Chiloiro G, Cellini F, Gambacorta MA, Indovina L, Valentini V. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. J Cancer Res Clin Oncol 2021;147:2057-68. [PMID: 33398447 DOI: 10.1007/s00432-020-03480-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
629 Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020;104:104-12. [PMID: 31283688 DOI: 10.1097/TP.0000000000002816] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
630 Loader M, Moravek R, Witowski SE, Driscoll LM. A clinical review of viral hepatitis. Journal of the American Academy of Physician Assistants 2019;32:15-20. [DOI: 10.1097/01.jaa.0000586300.88300.84] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
631 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
632 Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458-465. [PMID: 33303216 DOI: 10.1016/j.jhep.2020.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
633 Kovalic AJ, Cholankeril G, Satapathy SK. Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Transl Gastroenterol Hepatol. 2019;4:65. [PMID: 31620647 DOI: 10.21037/tgh.2019.08.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
634 Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. Journal of Hepatology 2020;72:277-87. [DOI: 10.1016/j.jhep.2019.09.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
635 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
636 Wei MT, Le MH, Landis C, Trinh H, Wong G, Le A, Zhang J, Cheung R, Nguyen MH. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. J Med Virol 2021. [PMID: 34219250 DOI: 10.1002/jmv.27168] [Reference Citation Analysis]
637 Zhang X, Wang T, Zhang KH, Chen SH, He YT, Wang YQ. Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels. Front Oncol 2019;9:1478. [PMID: 32038998 DOI: 10.3389/fonc.2019.01478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
638 Emamaullee J, Zaidi AN, Schiano T, Kahn J, Valentino PL, Hofer RE, Taner T, Wald JW, Olthoff KM, Bucuvalas J, Fischer R. Fontan-Associated Liver Disease: Screening, Management, and Transplant Considerations. Circulation 2020;142:591-604. [PMID: 32776846 DOI: 10.1161/CIRCULATIONAHA.120.045597] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 13.0] [Reference Citation Analysis]
639 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
640 Walter F, Fuchs F, Gerum S, Rottler MC, Erdelkamp R, Neumann J, Nierer L, Guba M, De Toni EN, Seidensticker M, Ricke J, Belka C, Corradini S. HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience. Front Oncol 2021;11:717792. [PMID: 34513694 DOI: 10.3389/fonc.2021.717792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Oranratnachai S, Rattanasiri S, Pooprasert A, Tansawet A, Reungwetwattana T, Attia J, Thakkinstian A. Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:654020. [PMID: 33869060 DOI: 10.3389/fonc.2021.654020] [Reference Citation Analysis]
642 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
643 Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
644 Hsu WF, Chang KC, Chen TH, Lin CH, Lin YC, Tsai MH, Chen PY, Wang HW, Chu CS, Peng CY. Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27000. [PMID: 34414987 DOI: 10.1097/MD.0000000000027000] [Reference Citation Analysis]
645 McGillen KL, Zaidi S, Ahmed A, Harter S, Yee NS. Contrast-Enhanced Ultrasonography for Screening and Diagnosis of Hepatocellular Carcinoma: A Case Series and Review of the Literature. Medicines (Basel) 2020;7:E51. [PMID: 32867068 DOI: 10.3390/medicines7090051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
647 Zhang W, Yang R, Liang F, Liu G, Chen A, Wu H, Lai S, Ding W, Wei X, Zhen X, Jiang X. Prediction of Microvascular Invasion in Hepatocellular Carcinoma With a Multi-Disciplinary Team-Like Radiomics Fusion Model on Dynamic Contrast-Enhanced Computed Tomography. Front Oncol 2021;11:660629. [PMID: 33796471 DOI: 10.3389/fonc.2021.660629] [Reference Citation Analysis]
648 Na SK, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. J Interferon Cytokine Res. 2019;39:703-710. [PMID: 31216229 DOI: 10.1089/jir.2019.0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
649 Geyer T, Clevert DA, Schwarz S, Reidler P, Gassenmaier S, Knösel T, Rübenthaler J, Schwarze V, Armbruster M. Diagnostic Value of CEUS Prompting Liver Biopsy: Histopathological Correlation of Hepatic Lesions with Ambiguous Imaging Characteristics. Diagnostics (Basel) 2020;11:E35. [PMID: 33375514 DOI: 10.3390/diagnostics11010035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
650 Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol 2019;13:667-81. [PMID: 31104523 DOI: 10.1080/17474124.2019.1621164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
651 Suoh M, Fujii H, Nagata Y, Kotani K, Hagihara A, Enomoto M, Tamori A, Inaba M, Kawada N. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma. Clin J Gastroenterol 2020;13:860-6. [DOI: 10.1007/s12328-020-01107-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
652 Chiu SH, Chang PY, Shih YL, Huang WY, Ko KH, Chang WC, Huang GS. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:5029-41. [PMID: 33235441 DOI: 10.2147/DDDT.S266470] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
653 Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
654 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
655 Chang J, Dumitrache A, Böhling N, Abu-Omar J, Meyer C, Strobel D, Luetkens J, Luu AM, Rockstroh J, Strassburg CP, Trebicka J, Gonzalez-Carmona MA, Marinova M, Praktiknjo M. Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). Sci Rep 2020;10:20682. [PMID: 33244180 DOI: 10.1038/s41598-020-77801-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
656 Komiyama S, Numata K, Moriya S, Fukuda H, Chuma M, Maeda S. Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports. World J Clin Cases 2020; 8(12): 2574-2584 [PMID: 32607334 DOI: 10.12998/wjcc.v8.i12.2574] [Reference Citation Analysis]
657 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
658 Albhaisi S, Shamsaddini A, Fagan A, McGeorge S, Sikaroodi M, Gavis E, Patel S, Davis BC, Acharya C, Sterling RK, Matherly S, Fuchs M, Gillevet PM, Bajaj JS. Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. Liver Transpl 2021;27:629-40. [PMID: 33492761 DOI: 10.1002/lt.25994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
659 Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2021:gutjnl-2020-323663. [PMID: 33741640 DOI: 10.1136/gutjnl-2020-323663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
660 Freeman E, Cheung W, Ferdousi S, Kavnoudias H, Majeed A, Kemp W, Roberts SK. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison. Scand J Gastroenterol 2021;56:942-7. [PMID: 34057003 DOI: 10.1080/00365521.2021.1930145] [Reference Citation Analysis]
661 Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. J Gastroenterol Hepatol. 2020;35:1595-1601. [PMID: 31975419 DOI: 10.1111/jgh.14990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
662 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
663 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
664 Lee CW, Tsai HI, Lee WC, Huang SW, Lin CY, Hsieh YC, Kuo T, Chen CW, Yu MC. Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal? J Clin Med 2019;8:E1736. [PMID: 31635078 DOI: 10.3390/jcm8101736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
665 Chen Z, Jiang H, Wang Y, Liang R, Xu L, Lai J, Shen J, Li J, Li D, Li S, Lei K, Zhou Q, Peng B, Peng H, Peng S, Kuang M. Three-day postoperative antibiotics reduces post-hepatectomy infection rate in hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2021. [PMID: 33948991 DOI: 10.1111/jgh.15528] [Reference Citation Analysis]
666 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
667 Wu L, Xie W, Zan HM, Liu Z, Wang G, Wang Y, Liu W, Dong W. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. J Mater Chem B 2020;8:4648-59. [PMID: 32373904 DOI: 10.1039/d0tb00735h] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 14.0] [Reference Citation Analysis]
668 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
669 Clemente-Sánchez A, Oliveira-Mello A, Bataller R. Moderate Alcoholic Hepatitis. Clin Liver Dis 2021;25:537-55. [PMID: 34229838 DOI: 10.1016/j.cld.2021.03.001] [Reference Citation Analysis]
670 Li K, Zhao G, Ao J, Gong D, Zhang J, Chen Y, Li J, Huang L, Xiang R, Hu J, Lin P, Wei Y. ZNF32 induces anoikis resistance through maintaining redox homeostasis and activating Src/FAK signaling in hepatocellular carcinoma. Cancer Lett 2019;442:271-8. [PMID: 30439540 DOI: 10.1016/j.canlet.2018.09.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
671 Wangensteen KJ, Chang KM. Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:27-37. [PMID: 32737895 DOI: 10.1002/hep.31481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
672 Chernyak V, Flusberg M, Berman J, Fruitman KC, Kobi M, Fowler KJ, Sirlin CB. Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging. Liver Transpl 2019;25:1488-502. [DOI: 10.1002/lt.25614] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
673 [DOI: 10.1101/2020.01.31.926972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
674 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4876. [PMID: 34638361 DOI: 10.3390/cancers13194876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
675 Gong XQ, Tao YY, Wu YK, Liu N, Yu X, Wang R, Zheng J, Liu N, Huang XH, Li JD, Yang G, Wei XQ, Yang L, Zhang XM. Progress of MRI Radiomics in Hepatocellular Carcinoma. Front Oncol 2021;11:698373. [PMID: 34616673 DOI: 10.3389/fonc.2021.698373] [Reference Citation Analysis]
676 Kim Y, Choi J, Kim SU, Lee M, Park M, Chung YE, Kim M. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy. American Journal of Roentgenology 2020;215:1354-62. [DOI: 10.2214/ajr.20.22802] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
677 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
678 Zhang XP, Liu YC, Chen ZH, Sun JX, Wang K, Chai ZT, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. Ann Surg Oncol 2019;26:1465-73. [PMID: 30767178 DOI: 10.1245/s10434-019-07223-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
679 Zhang X, Zhou T, Wang Z, Zhang F, Zhong C, Hu Y, Wang K, Chai Z, Chen Z, Wu M, Lau WY, Cheng S. Association of Preoperative Hypercoagulability with Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Liver Resection: A Multicenter Study. Ann Surg Oncol 2019;26:4117-25. [DOI: 10.1245/s10434-019-07504-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
680 Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31725-0. [PMID: 33387668 DOI: 10.1016/j.cgh.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
681 Kierans AS, Song C, Gavlin A, Roudenko A, Lu L, Askin G, Hecht EM. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. AJR Am J Roentgenol 2020;215:1085-92. [PMID: 32877248 DOI: 10.2214/AJR.20.22772] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
682 Wang JY, Feng SY, Xu JW, Li J, Chu L, Cui XW, Dietrich CF. Usefulness of the Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Focal Liver Lesions by Inexperienced Radiologists. J Ultrasound Med. 2020;Online ahead of print. [PMID: 32078173 DOI: 10.1002/jum.15242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
683 Li B, Zhao Y, Cai W, Ming A, Li H. Validation and update of a multivariable prediction model for the identification and management of patients at risk for hepatocellular carcinoma. Clin Proteomics 2021;18:21. [PMID: 34412596 DOI: 10.1186/s12014-021-09326-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
684 Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology 2021. [PMID: 33811766 DOI: 10.1002/hep.31845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
685 Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. Hepatol Res 2020;50:426-38. [DOI: 10.1111/hepr.13467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
686 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
687 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
688 Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep 2020;10:21742. [PMID: 33303924 DOI: 10.1038/s41598-020-78840-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
689 Kimura T, Takeda A, Tsurugai Y, Kawano R, Doi Y, Oku Y, Hioki K, Miura H, Nagata Y. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2020;108:1265-1275. [PMID: 32712256 DOI: 10.1016/j.ijrobp.2020.07.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
690 Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol 2021;36:569-80. [PMID: 33709606 DOI: 10.1111/jgh.15415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
691 Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
692 Smolock AR, Shaw C. Hepatic Microwave Ablation in Challenging Locations. Semin Intervent Radiol 2019;36:392-7. [PMID: 31798213 DOI: 10.1055/s-0039-1697003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
693 Kim SS, Eun JW, Cho HJ, Lee H, Seo CW, Lee GH, Yoon SY, Noh CK, Cho SW, Cheong JY. Effect of PTEN Polymorphism on the Development of Hepatitis B Virus-associated Hepatocellular Carcinoma. J Liver Cancer 2019;19:46-54. [DOI: 10.17998/jlc.19.1.46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
694 Nakamura H, Tanaka S, Miyanishi K, Kawano Y, Osuga T, Ishikawa K, Yoshida M, Ohnuma H, Murase K, Takada K, Yamaguchi H, Nagayama M, Kimura Y, Takemasa I, Kato J. A case of hypervascular tumors in the liver and pancreas: synchronous hepatocellular carcinoma and pancreatic metastasis from renal cell carcinoma 36 years after nephrectomy.Clin Case Rep. 2021;9:932-937. [PMID: 33598275 DOI: 10.1002/ccr3.3691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
695 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
696 Lee S, Kim KW, Jeong WK, Jeong SY, Hwang JA, Choi JS, Lee SG, Joh JW. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study. Ann Surg Oncol 2021. [PMID: 33751296 DOI: 10.1245/s10434-021-09772-8] [Reference Citation Analysis]
697 Makoyeva A, Kim TK, Jang HJ, Medellin A, Wilson SR. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study. Radiol Imaging Cancer 2020;2:e190014. [PMID: 33778701 DOI: 10.1148/rycan.2020190014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
698 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
699 Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2020;18:974-83. [PMID: 31357028 DOI: 10.1016/j.cgh.2019.07.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
700 Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, Shi J, Wu MC, Lau WY, Cheng SQ. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9:717-728. [PMID: 33299827 DOI: 10.21037/hbsn.2019.10.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
701 Tsilimigras DI, Hyer JM, Diaz A, Moris D, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC-0, A and B hepatocellular carcinoma. J Surg Oncol 2021;123:381-8. [PMID: 33174627 DOI: 10.1002/jso.26297] [Reference Citation Analysis]
702 Evangelista EB, Kwee SA, Sato MM, Wang L, Rettenmeier C, Xie G, Jia W, Wong LL. Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics. Diagnostics (Basel) 2019;9:E167. [PMID: 31671805 DOI: 10.3390/diagnostics9040167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
703 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
704 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
705 Tan HL, Goh BKP. Management of recurrent hepatocellular carcinoma after resection. Hepatobiliary Surg Nutr 2020;9:780-3. [PMID: 33299834 DOI: 10.21037/hbsn.2020.03.07] [Reference Citation Analysis]
706 Zhao J, Wu J, He M, Cao M, Lei J, Luo H, Yi F, Ding J, Wei Y, Zhang W. Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. Int J Hyperthermia 2020;37:624-33. [PMID: 32525724 DOI: 10.1080/02656736.2020.1774667] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
707 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
708 Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31272-6. [PMID: 32927050 DOI: 10.1016/j.cgh.2020.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
709 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
710 Wei J, Jiang H, Zeng M, Wang M, Niu M, Gu D, Chong H, Zhang Y, Fu F, Zhou M, Chen J, Lyv F, Wei H, Bashir MR, Song B, Li H, Tian J. Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study. Cancers (Basel) 2021;13:2368. [PMID: 34068972 DOI: 10.3390/cancers13102368] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
711 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
712 Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver Int. 2019;39:1704-1712. [PMID: 31319016 DOI: 10.1111/liv.14194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
713 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
714 Wilson SR, Burns PN, Kono Y. Contrast-Enhanced Ultrasound of Focal Liver Masses: A Success Story. Ultrasound Med Biol 2020;46:1059-70. [PMID: 32059917 DOI: 10.1016/j.ultrasmedbio.2019.12.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
715 Qi S, Zhang Y, Liu G, Chen J, Li X, Zhu Q, Yang Y, Wang F, Shi J, Lee CS, Zhu G, Lai P, Wang L, Fang C. Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma. Acta Biomater 2021;129:245-57. [PMID: 34082093 DOI: 10.1016/j.actbio.2021.05.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
716 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
717 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
718 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
719 Rhee H, Cho E, Nahm JH, Jang M, Chung YE, Baek S, Lee S, Kim M, Park M, Han DH, Choi J, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Journal of Hepatology 2021;74:109-21. [DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
720 Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, Croitoru AE, Ilieva RN, Natošević S, Nita AL, Kalev DN, Harpaz Z, Farbstein M, Silverman MH, Bristol D, Itzhak I, Fishman P. Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers (Basel) 2021;13:E187. [PMID: 33430312 DOI: 10.3390/cancers13020187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
721 Milot L. Does Hepatocellular Carcinoma Screening with US Work? Using the US LI-RADS Algorithm. Radiology 2019;292:398-9. [DOI: 10.1148/radiol.2019191105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
722 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
723 Saad AM, Abdel-Megied AES, Elbaz RA, Hassab El-Nabi SE, Elshazli RM. Genetic variants of APEX1 p.Asp148Glu and XRCC1 p.Gln399Arg with the susceptibility of hepatocellular carcinoma. J Med Virol 2021. [PMID: 34289138 DOI: 10.1002/jmv.27217] [Reference Citation Analysis]
724 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
725 Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31952209 DOI: 10.3390/cancers12010212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
726 Liu X, Khalvati F, Namdar K, Fischer S, Lewis S, Taouli B, Haider MA, Jhaveri KS. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?Eur Radiol. 2021;31:244-255. [PMID: 32749585 DOI: 10.1007/s00330-020-07119-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
727 Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Cheng YF, Wang JH, Yen YH, Liu TT, Li WF, Chen CH. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg 2021:S0002-9610(21)00226-9. [PMID: 33840448 DOI: 10.1016/j.amjsurg.2021.03.065] [Reference Citation Analysis]
728 Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q. Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. Onco Targets Ther 2020;13:9407-17. [PMID: 33061427 DOI: 10.2147/OTT.S257271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
729 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
730 Fowler KJ, Burgoyne A, Fraum TJ, Hosseini M, Ichikawa S, Kim S, Kitao A, Lee JM, Paradis V, Taouli B, Theise ND, Vilgrain V, Wang J, Sirlin CB, Chernyak V. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. Radiographics 2021;41:1611-31. [PMID: 34597222 DOI: 10.1148/rg.2021210009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
731 Tsilimigras DI, Pawlik TM. ASO Author Reflections: Recurrence Patterns and Outcomes After Resection of Hepatocellular Carcinoma Within and Beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol 2020;27:2332-3. [PMID: 32297083 DOI: 10.1245/s10434-020-08455-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
732 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
733 Kronenfeld JP, Ryon EL, Goldberg D, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Livingstone AS, Merchant NB, Goel N. Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. Ann Surg Oncol 2021;28:1929-36. [PMID: 32975686 DOI: 10.1245/s10434-020-09156-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
734 Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:882-888. [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
735 Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Reference Citation Analysis]
736 Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [